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The study in this thesis sets to explore the techniques to study the iron trafficking into the 
brain, and more closely in the substantia nigra par compacta (SNpc) region, and also, the 
altered iron loading mechanism, with particular application in disorders where specific 
compartments show elevated iron concentration, such as Parkinson’s disease (PD). Iron is 
essential for numerous biochemical reactions in the brain, but excess iron may produce 
reactive oxygen species that can induce cell death. The increase in iron concentration in 
this area has been shown repeatedly over the years, and it has been accepted as one of the 
main characteristics of PD. Another main characteristic of PD is the loss of neuromelanin-
containing dopaminergic (DA) neurone in the SNpc. Neuromelanin binds to and stores 
iron. The disappearance of neuromelanin in the SNpc is another indication that iron is 
involved in the progression of PD. The detail of iron involvement in PD, however, is still 
unknown. Attempts have been made in this thesis to create tools to answer some of the 
questions by image analysis to examine post-mortem human brain tissue; and building a 
novel computational model of iron transport into the brain. 
Synchrotron-based experiments, scanning transmission X-ray microscopy (STXM) and 
synchrotron X-ray fluorescence (SXRF), on post-mortem tissue are described in this thesis 
to investigate the spatial distribution and relative concentration of iron in the DA neurone 
and the redox state of the iron. These methods do not require dyes or fixing of the sample, 
thus allowing the native chemistry of the tissue samples to be better preserved. The 
investigation of the chemical state of iron using STXM method is of interest because it 
shows the region-specific toxicity state of the iron in the tissue and the neuromelanin. 
SXRF mapping can produce a high-resolution map of iron distribution in the tissue, and 
also calculate the relative concentration of iron in the DA neurone compared to the 
extracellular concentration. SXRF mapping and processing are described in detail in this 
thesis to inform how SXRF could be an excellent tool to study the involvement of iron in 
the PD. SXRF maps from experiments performed before this project are analysed and 
presented here. 
The iron absorption spectra from STXM mapping of 200 nm resin-embedded tissues 
revealed the presence of redox-active iron in the PD case but not in the control. This result 
supports the hypothesis that the cell death in PD is induced by oxidative stress. Carbon K-
edge examination of the neuromelanin in the tissue reveals a feature in the energy 
Abstract 
xix 
 
spectrum that is possibly unique to neuromelanin. However, further study needs to be done 
to confirm this finding. The result of such a study would allow label-free direct analysis 
of the chemical state of iron in the neuromelanin and to determine if the state changes in 
PD. 
Two computational models were built to create in silico representations of (1) iron 
transport into the interstitial fluid of the brain, and (2) iron transport into the DA neurones, 
using the modelling software COPASI. Model 1, the barrier systems model, was based on 
an existing well-developed concept from Drs Mitchell and Collingwood, and the original 
work in this thesis arose from testing and refining the model. Model 2, the DA neurone 
model, is completely original work, and designed so that it can be integrated with the 
barrier systems model in the longer term. The models are comprised from nonlinear 
ordinary differential equations which are used to characterise the kinetics of each chemical 
species incorporated. Model parameters values for compartmental volumes, and initial 
concentrations and rate constants for each species, were derived from experimental results 
from the literature. The simulations show that the regulatory activity of the brain barrier 
systems protects the brain against excessive iron loading, and a sensing mechanism may 
be required to prevent low brain iron concentration. Metabolic control analysis identified 
TfR as the key regulatory factor of iron concentration in the dopaminergic neurones and 
also the brain barrier systems. These new models are, to the best of our knowledge, the 
most comprehensive computational models of brain iron transport that have been 
developed to date. It is intended that they will provide in silico resources to explore the 
dysregulation of iron transport in PD and related disorders.  
The synchrotron-based mapping techniques and computational modelling presented in 
this thesis are excellent tools to study the implication of iron in PD. The SXRF mapping 
has the potential to produce a cell-specific concentration of iron as an input to the 
computational model, and the STXM mapping has the potential to reveal the basic 
knowledge for building the models, such as the compartmentalisation of the iron deposits 
in the neuromelanin. The synchrotron-based analyses produce results that are useful in the 
building of the computational model, and the computational models reveal the dynamic 
processes involved that cannot be observed from post-mortem analysis, so they are both 
critical. In combination, they offer a new approach to study unresolved questions in the 
field. 
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! Motivation 
Parkinson’s disease (PD), named after the English doctor Dr James Parkinson who 
described the illness in 1987, is a slow-progressing neurodegenerative disease. The 
disease affects the basal ganglia, which are involved in the control of arbitrary and 
spontaneous movement. Patients are not only affected by the motoric manifestation 
but also suffer from depression and anxiety, cognition difficulties, sleeping disorders 
and autonomic dysfunction such as digestive problems [2-4].  
A hallmark feature of PD is the loss of dopaminergic neurones in substantia nigra par 
compacta (SNpc). In the brain, iron is important for reactions such as myelin formation 
and energy production via changes in its valence states [5-7]. Iron’s ability to change 
between valence states, however, can lead to the production of toxic reactive oxygen 
species in overload circumstances. Iron readily participates in the oxidation and 
reduction reactions switching between ferric and ferrous states. An increase in iron 
concentration has been found in these neurones, and the overload of iron here has been 
implicated to be a likely cause of the neuronal damage in PD. The detailed mechanism 
of iron metabolism in the brain and how it is related to the unknown aspects of 
pathogenesis in PD remains unclear. 
Determining the pathogenesis of PD is a major area of interest. Key questions 
regarding PD pathogenesis that still need to be answered include [4]: (1) why are 
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dopaminergic (DA) neurones in the SNpc especially vulnerable; (2) which 
mechanisms underlie progressive cell loss of DA neurone in SNpc; and (3) what do 
Lewy bodies or α-synuclein reveal about disease progression.  
The full reasons for the death of neuronal cells in the Parkinson’s disease brain, 
including the DA neurons, are still unknown. The suggestion that excessive free 
radical formation and oxidative stress is a cause of the damage, indicates a link 
between iron accumulation and the PD pathogenesis [8].  
! Aims 
This study aims to develop ways to study the roles of iron in connection to the specific 
vulnerability of certain types of neuronal cell, including DA neurones in the SNpc c 
and the underlying mechanism of the disease progression. The areas that are 
investigated in this thesis are: 
1.! Using synchrotron based hard X-ray fluorescence (SXRF) to calculate the 
relative concentration of iron in the DA neurone compared to the surrounding 
cells. This is to study a possible reason that the DA neurones are more prone 
to dying compared to other surrounding cells in PD. The semi-quantitative 
result from this study may be used to validate the computational model built 
in this thesis. 
2.! Using scanning transmission X-ray microscopy (STXM) to study the 
compartmentalisation of iron deposits in the SNpc tissue. The STXM uses soft 
x-rays that allow the observation of the iron deposits within the biological 
materials. The findings of this study may inform how the iron uptake into the 
DA neurone is modelled using the computational model.  
3.! Building a model to describe iron uptake with the brain across the blood brain 
barrier (BBB) to create a new way of investigating the dynamics of brain iron 
trafficking. 
 
3 
 
4.! Building a computational model of the iron transport into the DA neurone of 
SNpc that allows for investigation of the iron dysregulation in health and PD, 
and to create simulations to test theories about why DA neurone cells in the 
SNpc are affected in PD. 
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! Iron and oxidative stress in Parkinson’s disease 
Parkinson’s disease (PD) is one of the most common movement disorders and 
neurodegenerative diseases [3]. Meta-analysis studies show an increase in the global 
incidence rate of PD. The overall incidence rate of PD is estimated to be 100 to 200 
per 100,000 people, and the annual incidence is estimated to be 15 per 100,000 [3]. In 
the UK, the estimated prevalence of PD in 2018 is around 66 million [9]. Genetic 
factors were identified in 5-10% of the patients [3], but the cause of PD in most cases 
is still unknown.  
The three major motor signs that are considered as the hallmarks of PD are 
bradykinesia, rigidity and tremor. PD is characterised by the loss of certain types of 
brain cell, including the dopaminergic (DA) neurones, and the presence of α-
synuclein-containing Lewy bodies in the substantia nigra par compacta (SNpc) [2]. It 
is this loss of DA neurone in the SNpc that leads to the reduced facilitation of voluntary 
movement [3]. The increase in the concentration of iron in SNpc in PD has led to the 
speculation that the cell death in this region was induced by iron-related oxidative 
stress. 
Iron in living cells dominantly exist in the forms of ferrous (Fe2+) and ferric (Fe3+) iron 
whose complexes readily undergo cyclic oxidation and reduction [10, 11]. This 
characteristic explains iron involvement in oxygen transport and other metabolic 
Chapter 2! Background 
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processes, such as DNA synthesis [12]. This activity, however, can generate oxygen-
derived free radicals called reactive oxygen species (ROS), which may cause 
biological damage. ROS are rapidly detoxified by the body defence mechanism under 
normal condition. Also, the body homeostatic mechanisms maintain the ideal iron 
level between optimum cell function and minimal ROS production due to excessive 
free iron concentration. However, when the iron homeostatic mechanism is disturbed, 
excessive amount of ROS are produced and end up overwhelming the cellular defence 
mechanism [13].  
Iron in healthy human serum (~20µM) is primarily in the Fe3+ form and safely bound 
to proteins such as transferrin, so they are not readily reduced to produce ROS [14].  
Intracellularly, iron is in its reduced, soluble Fe2+ form which constitutes the labile iron 
pool (LIP). In typical cells, the LIP concentration is ~ 2-3 µM. The LIP may be utilised 
in various cellular processes or oxidised and stored in a storage protein called ferritin 
to prevent the occurrence of unwanted oxidative reactions that generate ROS and 
subsequent cell damage. 
The concentration of iron in the SNpc in PD was reported by multiple studies to 
increase compared to control concentration [15-17]. The increased iron concentration 
has been linked to the severity of PD. The concentration of ferritin protein in this area 
does not increase in parallel with the increased iron concentration [17], suggesting a 
disruption in iron metabolism. 
One of the therapeutic methods that has been implemented to treat systemic iron 
overload is iron chelation [18]. Iron chelators are able to bind with excess iron and 
remove it from the system [19].  Recently, Devos et al. (2014) [20] published their 
observations from a clinical trial using an iron chelating drug in PD patients. 
According to their result, patients treated with Deferiprone (DFP), the chelating drug 
used in the clinical trial, show better motor performance and a reduction of the R2* 
value in the Substantia nigra which is consistent with a lowered iron concentration 
[20]. 
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! Brain iron metabolism 
2.2.1! Brain iron uptake 
Non-heme iron that is carried by the blood around the body is mostly in the form of 
Fe3+ and bound to a transport protein called transferrin (Tf). For transferrin bound iron 
(Tf-Fe3+) to be transported into the brain, it has to cross the blood capillary. The 
endothelial cells of the blood capillary in the brain are connected by tight junctions, 
creating the blood brain barrier (BBB), which makes passive transport of iron 
impossible. Tf-Fe3+ binds to a transferrin receptor (TfR) that is located on the surface 
of the luminal side of the BBB. The binding of two Tf-Fe3+ to the TfR initiates the 
receptor mediated transport, invaginating the TfR Tf- Fe3+ complex into clathrin-
coated pits which fuse the targeted membrane to form an endosome vesicle inside the 
BBB [21]. 
In the endosome, a proton pump increases the pH inside which results in iron being 
released from the transferrin. A ferric reductase enzyme converts Fe3+ into Fe2+ and 
subsequently, free Fe2+ is transported out of the endosome into the cytosol by divalent 
metal transporter 1 (DMT1) [22, 23]. The apo-Tf (empty transferrin) still bound to the 
TfR is recycled back to the luminal side of BBB. Systemic apo-Tf does not enter the 
brain interstitial fluid (ISF) [24]. 
In the cytosol of the BBB, the released Fe2+ joins the LIP and can be stored inside 
ferritin, an iron storage protein [25, 26], or transported out of BBB via an iron 
transporter protein called ferroportin. After Fe2+ is transported out by ferroportin, it is 
oxidised by iron oxidising protein. Then the Fe2+ that enters the interstitial fluid (ISF) 
of the brain binds to Tf expressed by the oligondendrocytes in the brain [27]. The 
presence of DMT1 in the BBB has been the subject of debate in the recent literature 
[28-31].  
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Tf-Fe molecules in the ISF are taken up by cells in the brain or constantly moving 
towards the cerebrospinal fluid (CSF) by bulk flow. It is postulated that CSF 
composition reflects that of ISF because the ISF and CSF are separated by highly 
permeable cellular layers that allow molecules up to the size of ferritin to pass through 
[32]. Tf-Fe in the CSF is transported back to the blood by a similar mechanism to the 
TfR mediated transport at the epithelial cells of the choroid plexus [7].  
2.2.2! Cellular regulation: iron response protein and iron response 
elements 
Iron response proteins 1 and 2 (IRP1 and IRP2) are proteins that post-transcriptionally 
control the expression of several mRNAs encoding proteins involved in the 
metabolism of iron. The mechanism involved is the binding of IRP to the 
corresponding iron response elements (IREs), a stem-loop structure in the untranslated 
region (UTR) of the target mRNAs [33]. This binding stabilises the mRNAs and 
initiates or inhibits the expression of the target mRNAs depending on the position of 
the IRE in the target mRNAs [34]. Examples of proteins that have IRE in their mRNAs 
are TfR [35], DMT1, ferritin [36] and ferroportin [37].  
IRP binding inhibits the translation of the target mRNAs if the IRE is located in the 
5’UTR of the target mRNAs, as in ferritin and ferroportin. The binding initiates the 
translation of the target mRNAs if the IRE is located in the 3’UTR of the target 
mRNAs, as in TfR and DMT1 [33, 37]. 
2.2.3! Transferrin and transferrin receptors 
Tf is an iron transport protein that has two iron binding site domains of equal size and 
affinity. The affinity of Tf for iron is very high at pH 7.4 so that Tf-Fe3+ is stable and 
not likely to be involved in the chemical reactions that create ROS. Tf is expressed in 
the brain, in the oligodendrocytes and the choroid plexus [36, 38]. In the plasma and 
other extracellular fluid, Tfs are found in the form of apo-Tf (free, no iron bound to 
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the Tf), mono-Tf (one Fe3+ bound to the Tf) and holo-Tf (two Fe3+ bound to the Tf) 
[39, 40]. 
TfR is the main iron importer protein in cells. It consists of a disulphide-linked 
transmembrane glycoprotein homodimer having a molecular mass of 180 kDa [41]. 
Each subunit of TfR has a molecular mass of 90 kDa that binds to one molecule of Tf, 
hence a TfR can bind to two molecules of holo-Tf [40, 42]. The binding of TfR to Tf 
is also influenced by the pH of the environment. At lower pH, the binding affinity of 
TfR for Tf increases, thus during the receptor-mediated endocytosis the Tfs stay bound 
to TfR and are released back to the plasma or extracellular fluid [39]. 
2.2.4! Divalent metal transporter 1 
Divalent metal transporter 1 (DMT1), also known as SLC11A2, Nramp2, and DCT1, 
is a proton-coupled metal transporter protein that has a broad substrate range that 
includes Fe2+, Mn2+, and Cu2+ [43-45]. It facilitates the direct transport of Fe2+ into a 
cell across the cell membrane and also the transport of Fe2+ across the endosomal 
membrane into the cell cytoplasm in the endosomal uptake pathway [46, 47]. The 
analysis of the mRNA expression indicates that the protein is present in many tissues 
including the brain. Gene expression of the DMT1 reveals four different types of 
DMT1 isoform: 1A/(+IRE), 1A/(-IRE), 1B/(+IRE) and 1B/(-IRE). 1A and 1B indicate 
the exon where the mRNA transcript starts, and in the brain, it is presumed that the 
DMT1 gene expression is exclusively on the 1B isoforms [48]. (+IRE) and (-IRE) 
signify the presence of the iron response element at the three prime untranslated region 
(3’ UTR) of the mRNA [49]. The (+IRE) isoforms are localised to the cell membrane, 
and the (-IRE) isoforms are not [50]. The four isoforms have the same turnover rate, 
functional properties and rate limiting steps. 
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2.2.5! Ferritin 
Ferritin is an iron storage protein that stores intracellular iron that is not needed for 
immediate use. Ferritin is ubiquitous and present in almost all organisms. A single 
ferritin protein could store up to 4500 atoms of iron within its core shell in the form of 
chemically less active ferrihydrite [51]. Most ferritin proteins consist of 24 subunits. 
There are two different types of ferritin subunit, heavy (H) and light (L) subunit. The 
predominant subunit in the brain is H, and the isoform distribution is cell specific. The 
ferritin in the neurone is predominantly H- ferritin [52]. The two subunit types have 
specific functions; the H subunit role is to perform oxidation of the cellular iron before 
it is stored, and the L subunits form the site for nucleation of the mineral core [53]. 
The ratio between the H and L subunits defines the dominant function of the ferritin 
in the cell and may change depending on a variety of extracellular stimuli such as 
inflammation [54].  
2.2.6! Neuromelanin 
Neuromelanin is a dark insoluble pigment localised to several types of neurone in the 
brain, particularly the DA neurones in the SNpc. In these cells, the neuromelanin 
pigment is located within cytoplasmic organelles with varying sizes ranging from 0.5 
– 3.0 µm. The granular aggregates of neuromelanin are 200-600 nm in size [55-57]. 
Mossbauer analysis of the neuromelanin reveals that its binding sites have similar 
features to human ferritin and that it binds to Fe3+ [58], however, there has been no 
mention of neuromelanin oxidizing Fe2+ as an equivalent process to that in ferritin. 
There are two different binding sites in the neuromelanin: the high affinity and low 
affinity binding sites. Iron bound to the high affinity sites is safely bound and stable, 
creating an anti-oxidant effect. However, in the iron overload condition, more iron 
starts to bind with the low affinity sites of neuromelanin, and iron binds to the low 
affinity sites might remain redox-active [59]. 
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2.2.7! Alpha-synuclein  
Alpha-synuclein (α-synuclein) is a protein mainly found in the brain tissue that has 
been proposed to play an important role in the modulation of dopamine release, by 
regulating the rate-limiting enzyme in the biosynthesis of dopamine in the SNpc [2, 
60]. The DA neurone appears to be selectively vulnerable to the toxicity of α-
synuclein [61]. Studies have shown that α-synuclein may be the building blocks of 
Lewy bodies, which are abnormal intracellular inclusions found in PD. α -synuclein 
binds with Fe3+ and Fe2+ with a binding constant of 1.2 x 1013 M-1 [62] and 5.8 x103 M-
1[63], respectively. The relationship between iron and the toxicity of α-synuclein has 
been observed in vitro. In numerous in vitro studies, iron was found to enhance the 
intracellular aggregation of α –synuclein [63, 64] and the incubation of α -synuclein 
with Fe2+ leads to the formation of ROS [65].  
2.2.8! Ferroportin 
Ferroportin is the only known mammalian cellular iron exporter that together with a 
ferrireductase is responsible for the cellular efflux of ferrous iron [66-68]. It is 
regulated post-transcriptionally by the regulatory hormone hepcidin. In the BBB, the 
expression of ferroportin has been documented in recent years [67, 69]. 
2.2.9! Hepcidin 
Hepcidin regulates the degradation of ferroportin. The binding of hepcidin on to its 
receptor site in ferroportin initiates the internalisation and subsequent lysosomal 
degradation of both ferroportin and hepcidin [68, 70]. The hepcidin protein responds 
to stimuli by the increased expression during iron overload and decreased expression 
during iron deficiency. Systemic hepcidin does not regulate brain iron uptake due to 
the lack of BBB permeability[68], so the expression of hepcidin in the brain has been 
studied by several groups. There is evidence that the hepcidin mRNA is found in the 
mouse brain and animal studies of hepcidin in the brain have shown rapid depletion 
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of overall brain ferroportin [71, 72]. However, there was no many evidence that the 
hepcidin mRNA is expressed in the human brain [73, 74]. 
2.2.10! Blood brain barrier 
The discovery of a barrier separating the brain and blood arose from the observation 
that certain compounds did not show pharmacological activity when injected into the 
blood of experimental animals, but presented visible effects when injected into the 
CSF. This hypothesis was further supported by whole body staining that shows Trypan 
Blue stained all tissues except the brain and the spinal cord when injected into the 
blood, and stained the brain tissues and spinal cord when injected directly into the CSF 
[75].  
The blood brain barrier (BBB) describes the property of the brain microvasculature 
which is made up of brain capillary endothelial cells (BCECs) [76, 77]. The surface 
area of the BBB is between 150 and 200 cm2 g-1 tissue constituting the largest interface 
for blood-brain exchange [77]. One of the morphological features that differentiates 
BCECs from non-neural vessels is the presence of tight junctions at the apical end of 
the inter-endothelial space. The tight junction consists of complex of proteins called 
occludin and claudins, and junctional adhesion molecules [77].  Together, these 
proteins create a membrane with high values of trans-endothelial electrical resistance 
(TEER) of 1800 Ω cm2, which significantly limits the permeation of molecules larger 
than 400 Da between the BCECs [78].  
The expression of TfR in the BBB has been found to be 6-10x the expression in the 
brain parenchyma [79]. Its distribution is specific to the brain with 10% of the TfR 
protein available at the surface and the rest located in the cytoplasm [78].  
2.2.11! Blood cerebrospinal fluid barrier 
The blood cerebrospinal fluid barrier (BCB) is made of the epithelial cells of the 
choroid plexus. The choroid plexus lines the brain ventricles, which are filled with 
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CSF. As the name suggests, the cells divide the CSF from the blood. The endothelial 
cells of the blood vessel in this region are not tightly bound, so it allows the particles 
to pass freely. It is the epithelial cells of the choroid plexus that have tight junctions 
between the cells, regulating the transport of iron across the barrier [80, 81]. 
The BCB also possesses proteins that are involved in the iron upregulation across the 
barrier, similar to the BBB. The presence of transferrin, transferrin receptors, ferritin, 
DMT1 and other iron transporters in the choroid plexus (i.e. BCB) have been 
demonstrated in the literature [7, 82, 83]. In the BCB, the TfR clusters around the 
nuclei and the ferroportin diffuses in the cytoplasm indicating the possibility of a two 
direction transport, but the DMT1 only exists on the side facing the CSF; this may 
indicate the direction of the iron flow across this barrier, from the CSF to the blood 
[7]. The DMT1 mediated efflux of iron in the BCB may constitute a clearance 
mechanism maintaining the iron concentration in brain extracellular fluid at a 
relatively stable level [7].  
2.2.12! Dopaminergic neurone 
Dopaminergic (DA) neurones are the neurone cells producing dopamine found in the 
SNpc and the LC, characterised by the dark brown pigment, neuromelanin. The 
measurement of iron in the SNpc using isothermal remanent magnetisation suggests 
an almost two fold increase in the concentration of iron for PD compared to healthy 
controls [17]. The concentration of the iron in the individual DA neurone was also 
shown to increase compared to the extracellular concentration by ~1.5x in PD [84]. 
The death of DA neurone has been linked to the aggregation of α-synuclein, however, 
it is still not known why the DA neurone is particularly sensitive to this mutation since 
α-synuclein is found in other areas in the brain. The presence of TfR, DMT1 and 
ferroportin has been found in DA neurone [85]. The TfR concentration in the DA 
neurone of SNpc was found to be lower than in other brain areas [86], and some studies 
showed that the level is almost undetectable [87]. 
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! Synchrotron-based technique 
Synchrotron facilities are particle accelerators that produce an intense beam of light 
primarily in the X-ray region of the electromagnetic spectrum [88]. The light can be 
further focused and tuned to produce the desired properties for specific requirement. 
This section will describe the principles of the two synchrotron-based techniques that 
are employed in this thesis.  
2.3.1! Synchrotron X-ray fluorescence (SXRF) 
Synchrotron X-ray fluorescence (SXRF) is a high-resolution mapping technique that 
captures the spectra of the sample. The high beam intensity and fine optics provided 
by the synchrotron facilities, enable the measurement of peak intensity for specific 
elements, or the full fluorescence spectrum in each pixel of the sample [88]. The 
intensity of the SXRF emission is proportional to the atomic abundance of the 
elements in the sample, which allows the quantitative measurement of the elements. 
2.3.1.1! X-ray fluorescence 
The X-ray fluorescence (XRF) principle is based on the interaction of the X-ray beam 
with the samples [88]. When the X-ray beam hits the sample, the electron absorbs the 
energy and is ejected from the atom. The hole left behind by the ejected electron is 
filled by an outer shell electron, which emits an X-ray during the ‘falling’ to the inner 
shell. The X-ray energy emitted is equal to the difference between the two energy 
levels. Therefore, the material emits radiation specific to the element of the atom 
present. The composition of the sample can be determined by using this characteristic 
fluorescence spectrum and the XRF spectrum of the sample [89]. 
Fluorescence lines are first named according to which shell the electron falls into, for 
example, if the electron falls into the K shell, then it produces K lines. The second 
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name depends on from which shell the electron falls, α is for the lowest energy 
transition, then β and γ [89].  
2.3.2! Scanning transmission X-ray microscopy (STXM) 
Scanning transmission x-ray microscopy (STXM) is a synchrotron-based technique 
that combines the principles of transmission electron microscopy and scanning 
electron microscopy. It allows the imaging of structures while simultaneously 
producing spectral information of the chemical composition of the material present. 
This technique has a spatial resolution of approximately 20 nm, and its X-ray beam 
exposure does not induce chemical changes in the iron material compositions [90].  
STXM is a soft X-ray microscopy with typical energy ranging between 100-1600 eV. 
Soft X-rays in the energy range between the C and O K-edge (284.2 eV and 543.1 eV) 
, termed the ’water window’ allows the investigation of hydrated, intact and unstained 
biological samples to be investigated [89]. In this thesis, the samples used are human 
brain tissue, and although, they are not hydrated, the application of this technique 
allows the imaging of the biological materials (protein structure) in the sample. Raster 
scanning the sample at an energy creates an energy specific image map across the 
sample. The absorbance spectra of the sample are generated by recording the level of 
x-ray transmission across multiple energies through the desired energy range, for 
example, an energy range used in this thesis is iron L-edge 700 – 740 eV. The result 
is that each pixel in the image of a structure has an individual X-ray absorption 
spectrum. STXM allows the examination of the materials within the ‘water window’ 
and the metals found in a single structure, making STXM a powerful tool for 
characterising the metal content of a biological system and their interactions [90]. 
2.3.2.1! X-ray absorption spectral 
When an energy from an incident X-ray beam generated by the synchrotron source 
hits the electron in the inner shell of the atom, the electron absorbs the energy and 
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excites to a higher energy shell. The photon energy of the X-ray beam is set to an 
energy range or ‘edge’ that excites the core electron of the material of interest. The 
absorption energy spectrum is sensitive to the oxidation state of the cation that absorb 
the X-ray. Thus, in this case, the recording the x-ray absorption spectrum across the 
iron L-edge produces the absorption spectrum of the oxidation state of the iron in the 
tissue material [90, 91]. 
 
The bright blue absorption spectra (Fe3+:Fe2+, 1:0), shown in figure 2.1, is the reference 
spectrum for pure Fe3+ minerals, which is characterised by the L3 edge absorption peak 
that is dominant at the 709.5eV and a shoulder peak at the 708 eV and the two lower 
intensity L2 edge absorption peaks at the 721 eV and 723eV. All the peaks arise from 
the X-ray absorption by the Fe3+ cations. The Fe3+ L3 edge shoulder peak at 708 eV 
and the L2 edge peak at 721 eV reside at the same energy as the Fe2+ L3 and L2 edge 
absorption peaks, respectively, that arise from the Fe2+ cations. The increase in the Fe2+ 
content of the iron material investigated will enhance these features, as shown in figure 
 
Figure 2.1 The iron L2 and L3 X-ray absorption edge spectra displaying the effect of varying the 
Fe3+ and Fe2+ ratios on the absorption features. The iron ratios are displayed above each spectrum. 
Reproduced with permission from Dr J. Everett (Everett 2015) [90]. 
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2.1. The sensitivity of the technique allows the identification of different phases of 
iron found in the biomaterial [90].  
! Modelling technique and tools 
Biochemical networks, such as brain iron metabolism, are intrinsically complex 
because of the large number of interacting components and their nonlinearity. The 
behaviour of these systems is not intuitive, and so a quantitative model is required to 
describe and understand better their functions [92]. Computational modelling systems 
biology provides a comprehensive and quantitative analysis, through computational 
modelling, for understanding the complex manner in which all of the components of 
a biological system interact. This approach allows for a comprehensive examination 
of the effect of the various components of the iron metabolic network over time. The 
model has the potential to be applied in a predictive capacity to analyse the behaviour 
of the iron metabolic system for simulated conditions and events [93, 94].   
2.4.1! Ordinary Differential Equations Based Modelling 
The biochemical networks are a set of chemical metabolites that undergo chemical 
reactions to convert into each other. The velocities of the chemical reactions are 
usually represented explicitly using mathematical expressions, such as ordinary 
differential equations (ODEs). Another representation available is probability 
distribution functions, but this method is not used in this thesis because it prefers a 
small number of metabolites. ODEs describe the dynamics of the concentrations of 
the chemical metabolites over time.  An ODE is composed of the algebraic sum of the 
terms representing the rates of the reactions that affect the chemical metabolites, which 
is given by [92]: 
!"
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where si is a stoichiometry coefficient representing the number of molecules of 
metabolite X consumed or produced in one cycle of reaction i, and vi is the velocity of 
the reaction i. A positive or negative sign indicates if the metabolite is produced or 
consumed, respectively. ODE models have been successfully applied to a variety of 
biological systems [95, 96], including liver iron metabolism [94].  
2.4.2! COPASI  
COPASI is a non-expert user friendly stand-alone software for systems biology 
modelling that provides a framework for deterministic and stochastic modelling [97]. 
COPASI offers the time course and steady state simulations. The steady state 
calculation in COPASI is carried out using a damped Newton method and forward or 
backward integration, depending on the user’s preference. The time course simulations 
are useful for model validation from experimental time course results and also provide 
the simulated/predicted time course. Another tool provided by COPASI is the 
sensitivity analyses. In COPASI, there are two frameworks for doing sensitivity 
analyses, metabolic control analysis (MCA) and generic sensitivities [92].  
2.4.3! Sensitivity analysis  
Sensitivity analysis describes how much a specific parameter affects the behaviour of 
the model. The sensitivity analysis is used to identify the important parameters that 
require accurate values. Less accurate values are sufficient for parameters that are 
identified as less important. Sensitivity analysis can also give hints on the parameter 
that has to change to create a specific effect. The local sensitivity analysis measures 
the effect of varying a single parameter on the model.  
MCA quantifies how much the rates of the various reactions in the model affect the 
concentration of the metabolites or the flux of the reactions at the steady state. It 
measures the distribution of control across the biochemical network [98, 99]. The 
results of MCA obtained by MCA measurement are concentration and flux control 
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coefficient. The values can be considered as the percentage change of the metabolite 
given a 1% change in the reaction rate [92].  
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In this chapter, synchrotron based imaging techniques, synchrotron X-ray 
fluorescence (SXRF) and scanning transmission X-ray microscopy (STXM), are 
presented as strong quantitative and semi-quantitative methods to investigate the iron 
in the substantia nigra par compacta (SNpc) in control and Parkinson’s disease (PD). 
The SNpc is of interest because it is one of the main regions that is affected by PD. 
The concentration of iron in this region increases in PD and there are losses in 
dopaminergic neurones, which contain of the pigment neuromelanin. The observed 
loss of these neurones, which leads to the resting tremor typically seen in PD patients, 
has been postulated to be caused by iron-induced oxidative stress. In this thesis, 
sensitive synchrotron imaging techniques were used to investigate the distribution of 
iron in tissue and cell level, as well as the state of the iron found. 
! Tissue sample preparation 
The tissue samples were received from Newcastle Brain Tissue Resource and the 
Canadian Brain Tissue Bank. This project was done under the multi-centre research 
ethics committee (MREC) approval for the project ‘Analysis and imaging of metal-
ion accumulation in neurodegenerative disease’ (REC reference number: 
07/MRE08/12) held by Dr Joanna Collingwood, valid until 2020. 
Chapter 3! Brain iron imaging using 
synchrotron X-ray mapping 
 
20 
 
3.1.1! Preventing iron contamination of tissue samples 
SXRF and STXM are highly sensitive spectroscopic mapping techniques. Any 
contamination in the sample could lead to false results, i.e. a signal that should not 
exist, or create a very strong signal that overshadows the neighbouring area. As iron 
is the main element of interest in this study, efforts were made to prevent iron 
contamination. This was done by not using metal tools in direct contact with the tissue 
samples, by using spectroscopically clean materials, and the highest purity chemicals 
during tissue processing. 
3.1.2! SXRF tissue sample preparation 
All of the sample preparation and data acquisition for the SXRF study were performed 
by Dr Joanna Collingwood and Dr Mary Finnegan before the start of this project. 
Details of how the samples were prepared have been published in their paper [17] and 
Dr Finnegan’s PhD thesis [100]. The protocol implemented was similar to the one 
described by$Antharam et al.(2012) [101]. All human tissue described in this thesis 
were either from the Newcastle Brain Tissue Resource (NBTR) at the University of 
Newcastle, UK, or the Canadian Brain Tissue Bank, Toronto, Canada. Full details are 
given elsewhere [100]. 
Three SNpc tissues from three different cases were examined using SXRF: one PD 
case and two controls. The reason for analysing this small set of cases was to test the 
feasibility of analysing human brain tissue by this method, in order to extract data for 
future use in computational modelling (chapter 4 and 5). The tissues used in this study 
are fresh frozen tissues, so they were not chemically fixed.  Fixing tissue with a 
fixative solution has been shown to leach metals from tissue and potentially change 
the distribution, concentration and the state of metal in the sample. All tissues were 
stored in -80°C freezer at the metal trace lab at the School of Engineering, University 
of Warwick. They were received with case numbers assigned by the source brain bank. 
They were renamed to ensure anonymity with letter C or PD to represent the disease 
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state and a number (1, 2,...). The details of the tissue analysed in this study are listed 
in table 3-1.$
Table 3-1 The details of the samples studied using SXRF mapping. C is control and PD is Parkinson’s 
disease. 
Case Number Sex Age 
C1 M 85 
C2 F 90 
PD1 M 90 
 
Before the tissue could be processed, it was kept overnight at a temperature of -25° C. 
Just before the dissection, the temperature of the tissue was increased to just below 0° 
C so it was soft enough to cut without fracturing the block. The cutting was performed 
in a low temperature environment, inside a cryostat or a biohazard hood cooled with 
dry ice. This was done to prevent the tissue from uncontrolled defrosting. The tissue 
was cut using a ceramic blade to prevent metal contamination. The tissue was then 
stored frozen in an airtight container. 
3.1.2.1! Sample sectioning: Cryomicrotome 
The tissue samples containing the region of interest were sectioned to a thickness of 
30 µm using a cryomicrotome. Figure 3.1 shows the placement of the tissue sample 
and the blade on the microtome. A Leica Jung CM3000 cryomicrotome was used. A 
sapphire (non-metal) blade was installed to the cryomicrotome for the sectioning to 
prevent metal contamination. The prepared sample was mounted on the sectioning 
block of the cryomicrotome using Tissue-Tek mounting medium, but the sample was 
not embedded in the mounting medium to avoid introducing potential sources of metal 
contaminations.  
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Figure 3.1 The set-up for tissue sectioning. The sample was not embedded in the mounting medium. 
There was only enough mounting medium to attach the sample on to the chuck. A sapphire blade was 
used for sectioning to prevent metal contamination. The paintbrush was used to control the section 
and prevent the tissue from curling after sectioning. (reproduced with permission from Dr M.E. 
Finnegan (Finnegan 2013) [100]) 
The sample was left covered in the cryomicrotome for at least an hour to bring the 
temperature to ~ -17° C. Other instruments used during the sectioning, such as the 
sapphire blade and paintbrush, were also brought to the same temperature. The 
sapphire sectioning blade was set in the metal blade holder at a 10° angle and with 
approximately 15 mm of the blade protruding from the clamp. This was done so that 
the cut sections fell onto the blade and not the metal surface to avoid metal 
contamination. During the sectioning, the tip of a paintbrush was used to control and 
transfer the sections onto a quartz slide and to prevent the sections from curling. The 
sections were cut at 30 µm based on previous SXRF experiment experience by our 
group. A strong SXRF signal (above background) was obtained from 30 um thick 
sections, using a dwell time of 1 second. 
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The sections on the quart slides were left to air dry inside a biohazard hood for at least 
4 hours. The hood minimised the probability of particulate contaminants landing on 
the samples. After drying, the slides were subsequently covered with X-ray transparent 
Kapton film, to shield the samples from contamination outside the hood. PAP pen was 
used to fix the slides and the films around the edge and then they were sealed with 
epoxy resin. This step satisfied mandatory the health and safety requirements of the 
Diamond Light Source. 
3.1.3! STXM tissue sample preparation 
The STXM experiment is from a collaborative study including Dr Neil Telling and Dr 
James Everett from the University of Keele. The sample selection and the initial 
sample dehydration process for the samples selected for analysis in this thesis were 
performed by Dr Joanna Collingwood. The subsequent dehydration and embedding 
process was performed by Dr James Everett, assisted by the author. The tissues 
examined in the STXM study were fresh frozen tissue received from brain banks (as 
in section 3.1.2). They were stored under ethical approval in the -80°C freezer in the 
Trace Metals in Medicine laboratory in the School of Engineering, University of 
Warwick.  
Two SN tissues from two different cases were prepared and measured using STXM 
(table 3-2): one PD case and one control. The control case investigated using STXM 
is the same case analysed using the SXRF, C1. The PD case (PD2) is independent of 
PD1 analysed by SXRF. 
Table 3-2 The details of the samples studied STXM mapping. C is control and PD is Parkinson’s 
disease 
Case Number Sex Age 
C1 M 85 
PD2 M 85 
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During the STXM sample preparation, the tissue blocks were brought to room 
temperature, but the initial sample selection and excision were performed inside a 
cryostat to keep the remaining tissue block frozen. Inside the cryostat, several cubes 
of ~1mm3 of substantia nigra tissue were cut from the rest of the tissue block. A 
ceramic blade was used to cut the tissue to avoid iron contamination. The tissue blocks 
were placed on a clean weighing boat for the dehydration process. The dehydration 
process was executed in a biosafety cabinet.  
Inside the biosafety cabinet, the tissue blocks were immersed in an alcohol solution to 
remove the water content from the tissues slowly. The solution was changed every 2 
hours (5 times in total) and with each change, the concentration of the alcohol solution 
was increased: 25% (75% pure water), 50% (50% pure water), 75% (25% pure water), 
and 100% to anhydrous ethanol (twice). Anhydrous ethanol is ethanol after trace water 
content has been removed using zeolite. Failure to fully dehydrate tissue samples 
would result in poor section integrity. After the last alcohol immersion step, the tissue 
blocks were moved into a glass vial for the embedding process. 
The resin used for the tissue embedding was comprised of a 1:1 molar ratio of 
trimethylolpropane triglycidyl ether and 4,4’-methylenebis (2-
methylcyclohexylamine). This resin was chosen because it is STXM compatible, 
containing no carbonyl or aromatic groups, which means it does not have a strong 
carbon K-absorption edge spectral feature. Chemistry of the iron in the tissue is also 
unaffected by the resin [102, 103]. 
To allow the resin to penetrate the tissue sections completely, the tissue sections were 
not directly embedded in 100% resin solution. Like the dehydration process, the 
embedding process started with the immersion of the tissue sections in a solution with 
25% resin (75% ethanol). The solution was replaced a total of seven times with higher 
resin concentration solution every 2 hours. The resin concentrations used were 25%, 
50%, 75% and 100% (4 times). A fresh resin was made for every resin change. The 
resin was made inside a fume hood and was stored inside a glass vial because plastic 
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is not a compatible container for this resin. Once it was in a closed glass vial, it was 
safe to move the resin into the biosafety cabinet where the embedding process was 
carried out. Inside the biosafety cabinet, the resin solution was transferred into the 
glass vial containing the tissue sections using a disposable pipette. The glass vial was 
then placed on a slowly moving rotating mixer to keep the resin from setting. 
After the fourth 100% resin immersion, all tissue sections in the glass were transferred 
into individual 0.5 ml Eppendorf tubes. A fresh resin was transferred into the tubes. 
The tubes were then put inside a 60°C oven for 6 hours to let the resin to set. If the 
resin did not start to set after 4 hours, the resin would not set. The reason for the resin 
not setting might be because of the mixing of a slightly different molar ratio of the two 
resin solutions and the resin not being well mixed. Great care was taken to ensure that 
the embedding was successful. 
3.1.3.1! Sample sectioning: Ultramicrotome 
Once the resin had set, the resin embedded tissue was sectioned into thin sections (100 
– 200 nm) using an ultramicrotome. The resin embedded tissue was removed from the 
Eppendorf tube and fixed on the sample holder of the ultramicrotome. Depending on 
where the tissue sample was located in the resin block, excess resin was trimmed away 
using a clean room standard razor blade. The razor blade contains iron, so the cutting 
was stopped when there was ~1 mm of resin left between the razor and the tissue 
sample, to ensure that the razor never came into contact with the tissue sample. The 
sample was then placed on the ultramicrotome.  
The trimming was continued using a glass knife on the ultra-microtome. Glass knife 
is used for trimming because it is relatively cheaper than the diamond or sapphire 
knife. Once the knife reached the tissue block, the resin block was trimmed to create 
a square section of 1 - 1.5 mm2.  
The glass knife was exchanged for a diamond knife to section the tissue sections to be 
collected for the STXM analysis. The diamond knife had a boat that was filled with a 
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10% ethanol solution in 18MΩ ultrapure water. When a section of the sample was cut, 
it would float on the ethanol solution in the boat. The section was then transferred on 
to a copper microscopy grid (100 mesh) by using the grid held between a pair of 
tweezers to scoop the sample or using a loop to transfer the section on to the grid. A 
bright field picture and transmission image of the sections on the grid was taken and 
then the grids were stored in a grid box for transport to the synchrotron facility. 
! Mapping methods 
3.2.1! SXRF mapping 
SXRF mapping was performed on the 30 µm thick tissue sections at the microfocus 
spectroscopy beamline (I18) at the Diamond Light Source (DLS), in Oxford, UK. Data 
were collected during three separate visits to the DLS over a period of 3 years (2008 
– 2010). Table 3-3 lists all the samples analysed. Experiments A and B were performed 
by Dr Joanna Collingwood and experiment C was performed by Dr Mary Finnegan 
before the start of this PhD. The data collected from these experiments were processed 
by the author to produce metal maps illustrating the distribution and relative 
concentration of iron in the sample. 
Table 3-3 List of all the Diamond Light Source (DLS) experiments and the samples presented in this 
thesis. C represents control cases and PD represents the Parkinson’s disease cases. JFC: Dr J.F. 
Collingwood and MEF: Dr M.E. Finnegan 
Main experiment investigator Experiment Date Case number 
JFC A Oct 2008 PD1 
JFC B Sep 2009 C1 
MEF C Aug 2010 C2 
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3.2.1.1! SXRF Experimental setup 
The setup of the SXRF experiment is shown in figure 3.2. The quartz slide containing 
the tissue sections covered with the Kapton film was mounted on to the slide holder. 
The sample holder then was fixed on the sample stage, which was positioned at a 45° 
angle to the incident X-ray beam (I0). The multi-channel detector was positioned 
perpendicular to the I0. A microscope camera was set focusing on the focal point of 
the beam. This camera allows the experimenter to view the sample position while 
moving the sample back and forth along the z-direction to bring the sample to the focal 
point of the beam. Once the sample was in the focal plane, the z-axis position was kept 
 
Figure 3.2 SXRF mapping set-up reproduced with permission from Dr M.E. Finnegan (Finnegan 
2013) [100]. a) a photograph of the configuration of the experimental set up taken by Dr M.E.  
Finnegan at I18, b) the photograph of the sample fixed on the slide holder. The slide is covered by 
kapton film, c) the schematic of the experimental set-up corresponding to a). 
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constant. When the sample is in focus, the X-ray beam is at or near the centre of the 
beam. To create a map, the sample stage can also be moved horizontally (x-axis 
direction) and vertically (y-axis direction).  
Once the slide holder with the sample slide was mounted on the sample stage, the 
coordinate of the map was set. Optical microscopy and staining of adjacent sections 
were used to locate regions of interest for mapping. Due to time consuming mapping 
and limited experiment time, it was important to select carefully the area to be mapped 
at high resolution. When mapping is not in progress, e.g. when the mapping coordinate 
is being selected, one of the beam shutters was closed to prevent the beam from 
reaching the samples. This stops the samples from being damaged by unnecessary 
prolonged exposure of high intensity x-rays. The signal from the slide (excluding 
tissue) was also measured so later it could be subtracted during data processing. 
3.2.1.2! Data acquisition: Creating an SXRF map 
The samples were mapped using the step mode. In this mode, the sample was moved 
by one step at a time. The detector collected the signal for a specified dwell time, one 
second per point, before the sample was moved to the next point in the map. It took 
approximately 0.5 seconds for the sample stage to move from one point to the next. 
The step size was matched to the beam spot size, which was 60 x 60 μm for the main 
map. Thus each pixel in the main map contains compositional information from a 
volume of 60 x 60 x30 μm (section thickness) of wet tissue. 
3.2.2! STXM mapping 
The STXM mapping was performed on the Molecular Environmental Science (11.0.2) 
beamline at the Advanced Light Source (ALS) (Berkeley, USA). The data were 
collected during one visit to the ALS in 2015. Dr Neil Telling was the head 
investigator of the experiment. The aim of the experiment was to obtain images of the 
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iron distribution and the X-ray absorption spectroscopy data to indicate the redox state 
of the iron in the SNpc tissue.  
3.2.2.1! STXM Experimental Setup 
Before the start of the experiment, the samples to be imaged were selected based on 
images of the resin sections on the copper grid taken with a light microscope. Optimal 
sections (i.e. sections with the flattest area on the grid holes) were mounted onto 
stainless steel microscopy plates for the STXM imaging. The plates were then inserted 
onto the sample holder in the STXM chamber. Unlike the SXRF beamline at DLS, 
there is no camera overlooking the set up to view the sample position in this beamline. 
However, there is a window on the STXM chamber that the experimenter can look 
into to check that the zone plate does not collide with the sample during focusing.  
Images of the sections of the slide were used to determine the region of interest on the 
tissue section. Due to time consuming mapping and limited experiment time, it was 
important to select carefully the area to be mapped at high resolution. When mapping 
is not in progress, the beam shutters automatically close to prevent the beam from 
reaching the samples. This stopped the samples from being damaged by unnecessary 
prolonged exposure of high intensity x-rays.  
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3.2.2.2! Data acquisition: STXM map 
A large coarse scan of the sample, typically 2mm2, was performed to obtain the full 
image of the section at the peak carbon K-edge absorption energy for the tissue protein 
structure (288.3 eV). This large map was used to identify the area of interest. The 
region of interest was raster scanned at 288.3 eV to show the biological structure at a 
resolution of 100 – 600 nm. Another scan of the same area was taken at 290 eV, which 
is the peak carbon K-edge absorption energy for the epoxy resin used in the embedding 
process. Subtracting images obtained at 290 eV from images obtained at 288.3 eV 
removes the carbon artefacts from the resin material, as shown in figure 3.3. This 
subtraction process is done using the aXis2000 software [104]. 
The carbon K-edge absorption spectra for the region of interest in the biological 
sample was performed by doing multiple raster scans at different energies over the 
same area, known as carbon ‘stacks’. These stacks were performed at an energy 
resolution of 0.1 eV. The carbon stacks maps are performed at a lower spatial 
resolution than the single raster map due to time constraints.  
 
Figure 3.3 Subtraction process performed in Axis2000. (a) image at the protein peak carbon K-
edge absorption energy, 288.3 eV. (b) image at the resin peak carbon K-edge absorption energy, 
290 eV. (c) image created by subtracting image  (b) from (a). The subtraction also removes 
artefact from the image. 
 
a b c 
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To reveal the iron content within the tissue, another raster scan of the same area was 
performed at the iron L3-edge, similar to the raster scan at the carbon K-edge energy. 
The iron peak scan is performed at the energy of 710 eV and the off peak scan at the 
energy of 705 eV. The difference map of these two scans creates an artefact-free map 
that shows the location of the iron deposit. Further scans with higher spatial resolution, 
approximately 30 nm at the iron L3-edge, were made to confirm the presence of the 
iron deposit. Iron stack scans were performed at the iron L-edge absorption energy to 
obtain detailed x-ray absorption spectra of the iron deposit. The iron absorption spectra 
are compared to the reference iron absorption spectra to determine the oxidation state 
of the iron deposits.  
3.2.2.2.1! Neuromelanin absorption spectroscopy 
During the experiment, a carbon stack map of a tissue area that was suspected to 
contain neuromelanin was observed. By going through the stack images at different 
energies, an energy that reveals only neuromelanin-like granular structure within the 
protein tissue structure was determined. The images at different energies are shown in 
figure 3.4. The image at the carbon K-edge energy 286 eV shows a very clear picture 
of the granular structure but not the surrounding protein. This energy was used during 
the experiment to image different areas that might include neuromelanin. Carbon K-
edge energy 278 eV was chosen as the off peak energy for the candidate neuromelanin 
image mapping because less features are shown at this energy. The final candidate 
neuromelanin parametric image is created by subtracting the image at 278 eV from 
that at 286 eV. 
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! Data processing 
3.3.1! SXRF data processing 
Each SXRF map file collected consists of the fluorescence spectrum for each data 
point. This section describes how comparison maps of the relative iron were created: 
fitting of the fluorescence peaks, calculating the area under the peaks, data 
normalisation and background subtraction. PyMCA and ImageJ, an open source 
software, were used to process the data. 
Each set of SXRF map file is accompanied by an RGB file. The RGB file comprises 
the distribution and signal intensity of the key metals that are expected in biological 
tissues. The signal intensity data are not fitted to the fluorescence peak at this stage, 
and are not corrected for overlapping peaks or background signal. To obtain the 
relative metal concentration of the metal peaks, the peaks of the SXRF signal from 
these files, therefore, have to be fitted. 
  
Figure 3.4 Images of the carbon K-edge STXM protein map selected from the carbon stacks 
performed over the carbon K-edge. The selected energy map are: (a) 278 eV, off peak energy, (b) 
286 eV, the proposed energy for the neuromelanin-like granular structure, (c) 288.3 eV, peak 
energy for tissue protein structure, and (d) 290 eV peak energy for the embedding resin. Mapping 
at 286 eV shows the most granular features without the tissue protein structure.  
 
a b c d 
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3.3.1.1! SXRF spectral fitting 
The fluorescence spectra of the SXRF map were fitted using PyMCA. The fitting 
process starts with calibrating the energy of the detector channels. Known 
characteristic peaks of fluorescence spectra were used to set the detector channels to 
the correct energy, as shown in figure 3.5. Next, the peaks and background signal and 
the edge of the scatter peak were fitted using the ‘Advanced Fit’ tool. This fitted the 
average fluorescence spectra of the whole map. Once the best fit for the average 
spectra was obtained, this was then used to fit individual spectra at each pixel on the 
map. This fitting setting was saved and then reused to fit spectra of new maps with 
adjustments, if necessary. The fitted output file was then opened using the RGB 
correlator tool in PyMCA. In this tool, a distribution map for each of the individual 
 
Figure 3.5 Calibration of the energy of the detector channels in PyMCA software. The element 
for the fluorescence peaks are identified and saved. The peak energy for Fe Kα is 6.4039KeV. 
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metals fitted could be viewed and the relative concentration of the metals could be 
normalised as described in the next subsection.  
3.3.1.2! Data normalisation  
To produce a relative concentration metal map that is comparable across the sample 
and between different samples, the spectra must be corrected to account for possible 
experimental errors. These errors are: varying electron beam intensity, attenuator used 
in the experiments, and a shift in the detector position. This section will explain how 
these errors were corrected. 
Although the energy of the beam at DLS is stable the intensity of the electron beams 
could vary depending on the time of data collection and also between experiments. 
The electron beam intensity has a step profile due to the difference in the intensity of 
the beam as the beam decays over time and is periodically topped up. The solution is 
to normalise the spectra in each pixel in the map to incident flux, I0, for that pixel. 
Normalisation to I0 also corrected for changes in the intensity of I0 due to the insertion 
of attenuators into the x-ray beam. This process was done using the RGB correlator 
tool in PyMCa, following the spectral fitting described in the previous subsection. The 
I0 map from the corresponding RGB file was opened in RGB correlator tool. Then, 
using the image calculator tool in the software, each metal map was normalised to the 
I0 and saved into Tiff format. 
3.3.1.3! Region of Interest (ROI) analysis in ImageJ. 
ImageJ is a free open-source software. It allows the measurement of signal intensity 
in the ROI in the normalised metal maps. Each pixel in the saved Tiff file contains the 
fitted and normalised area under the fluorescence peak for the chosen metal (e.g. iron, 
copper and zinc). By drawing ROIs around different tissue structures, the normalised 
SXRF signal intensity of these structures could be measured. 
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3.3.1.4! Background subtraction 
The amount of fluoresced x-ray beam received by the detector is affected by the 
distance and angle of the detector relative to the sample. However, the position and 
angle could vary considerably between experiments and even over a single experiment 
due to detector movement during sample changes. A marker was placed to minimise 
such changes but slight variation was still possible. To correct for this error, the 
average background signal from the quartz slide was subtracted from each pixel of the 
metal map with ImageJ.  
3.3.1.5! Signal threshold  
Subtracting the average background signal from the slide for each pixel produced a 
pixel intensity value approximately close to zero. This value was set as the lower 
threshold limit for the map signal by setting the value to ‘NaN’ in the ‘adjust threshold’ 
function in ImageJ. This will automatically exclude areas with signal intensity falling 
below this threshold, such as areas of tears or cracks in the tissue. An upper threshold 
was set to cut out high intensity signals from contamination such as dust and folded or 
curled area. The threshold was set with caution as not to remove true variation in metal 
signal in the tissue. 
3.3.1.6! Sources of measurement uncertainty 
When comparing the metal concentration between different tissues, the thickness of 
all the tissue sections were assumed to be consistent. Non-uniform thickness may be 
one potential source of error. This error was minimised by using, at the time, a recently 
serviced and calibrated cryo-microtome. SXRF spectra fitting and background 
normalisation may also provide a source of error.  
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3.3.1.7! Segmentation of SXRF images 
The samples here were segmented and analysed as a feasibility exercise to show that 
the analytical methods included in this chapter could be used in the future to fully 
  
  
Figure 3.6 Images of the step to step process performed to determine the area of the optical image 
that corresponds to the high resolution map 1 and 2. (a) optical image of the whole tissue section. 
(b) the corresponding iron fluorescence map of the whole section. (c) the area where the high 
resolution scan were performed. The areas are labelled 1 and 2. (d) overlapped image of the 
optical image over the fluorescence map to determine the optical image that corresponds to the 
high resolution fluorescence map. 
 
a b 
c d 
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quantify the parameters of interest using SXRF, and that the quantified result could 
support computational modelling.  
After the background subtraction and the threshold setting, relative fluorescence signal 
intensity can now be measured. To obtain the concentration of the iron in the cells and 
in the neuropil (area of the tissue that immediately surrounding the cells), the map has 
to be segmented by comparing the map to the corresponding optical image. From the 
optical image, cells can be identified and segmented from the rest of the area. The 
‘freehand selection’ tool in ImageJ can be used to draw around the area of interest, in 
this case, the cells and measure the mean intensity of the selected area. This section 
describes the process of finding the right area in the optical image that corresponds to 
the high resolution fluorescence map and the segmentation process.  
 The optical image and the whole area map for PD1 tissue map are shown in figure 
3.6a. By comparing the coordinate value for the higher resolution with the coordinate 
value from the whole fluorescence map the approximate area with the higher 
resolution can be found. The process is shown in figure 3.6b. Next, by overlapping the 
two maps, the optical image and the fluorescence image, together, the approximate 
area where the high resolution maps were taken could be determined, shown in figure 
3.6. Once the area of the corresponding optical image for the highest resolution map 
is found, the cells are segmented from the area. 
In ImageJ, the cell areas, determined by comparing to the optical image, are selected 
using the ‘freehand selection’ tool. Holding the shift button while selecting, allows 
multiple areas to be measured at the same time. Once all the cell areas are selected, 
the ‘measure’ function in ImageJ calculates the mean intensity in the pixels selected. 
This gives the mean intensity of the iron peak in the cells. The intensities of the 
neuropil area are calculated by first creating a mask (‘create a mask’ function) of the 
measured cells area, then by using the ‘threshold’ function on the mask area, the 
neuropil areas can be selected.  The ‘analyse particle’ function saves the area, which 
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then can be applied to the original map to calculate the neuropil area, using the same 
measure function.  
Because the iron concentration in DA neurones is significantly above background, it 
may be feasible to perform segmentation even when limited optical information is 
available using the threshold function in ImageJ. The process begins using the 
threshold function to select areas with high iron signal intensities. The areas are 
selected by comparing to the fluorescence map from PyMCA. Then the process is 
similar to the one described above but without the need of using a mask. The ‘analyse 
 
 
Figure 3.7 The segmenting process of tissue C2 with the guidance of fluorescence image from 
PyMCA. (a) fluorescence image of tissue section C2. (b) image of the fluorescence map with the 
cell areas circled in yellow and filled in red. (c) image of the fluorescence map with the rest of 
the areas filled in red. 
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particle’ function saves the area selected by the threshold then the areas are calculated 
by using the ‘measure’ function. Setting the threshold on the other end selects the areas 
that were not selected as the cells. The process is shown in figure 3.7. 
3.3.2! STXM data processing 
3.3.2.1! Background subtraction 
 aXis2000 (Analysis of X-ray Images and Spectra 2000) is a free imaging software 
program that was developed to process STXM data. In ‘stack process’ in aXis2000, 
the background signal attributed to the beamline signal is removed from the carbon or 
iron stacks images by converting the transmitted x-ray into optical density (OD). OD 
is given by [90]: 
OD = ln+(89 8) 
where I0 is the incident x-ray beam flux and I is the x-ray beam flux transmitted 
through the sample. In the ‘stack process’ window, the I0 is obtained by selecting the 
area that does not contain tissue material (resin only area). The ‘→OD’ function allows 
the OD conversion to be done automatically on the stacks map.  
3.3.2.2! Energy map alignment 
X-ray beam drift may occur during the long scanning time, up to 2 hours, for the 
carbon or iron stacks imaging. The zimba function in aXis2000 corrects this shift by 
aligning the multiple images taken at different energies to a common feature. Once the 
background has been subtracted from the images and the multiple images in the stack 
maps have been aligned, the spectra for a specific region of interest can be selected 
and saved in the ‘stack process’ window in aXis2000. The spectra are saved in the 
form of .txt file, which can be opened in Microsoft Excel or OriginPro 9.1 for plotting 
and further processing.  
Eq. 3.1 
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3.3.2.3! Composite map 
The composite map in this chapter is created using ImageJ. The subtracted images to 
be overlaid, protein structure (288.3 eV and 290 eV), iron deposit (705 eV and 710 
eV) and neuromelanin-like granular structure (278 eV and 286 eV), are opened in 
ImageJ. These images have to have the same pixels and bits for the composite map, 
and these maps usually do because they are taken at the same size and resolution. In 
the ‘image tool’, in ImageJ, the ‘make composite’ function can be used to overlay up 
to seven images using seven different colours, red, green, blue, grey, cyan, magenta 
and yellow. For the composite maps in this chapter, red is chosen to represent the iron 
deposit, green to represent the neuromelanin-like granular structure and cyan to 
represent the tissue protein structure. The brightness level for each image is adjusted 
to provide the best contrast. Then, the images are combined into a single RGB image 
by selecting the ‘stack to RGB’ function. 
3.3.2.4! Spectral smoothing 
Spectra smoothing is generally avoided in this chapter to preserve the peak feature of 
the spectra, except for the iron deposit G in figure 3.15. Iron deposit G spectrum was 
noisier than the rest, so spectral smoothing was performed to enable better peak 
identification. The smoothing is performed using the software, OriginPro 9.1, using 
the ‘smoothing’ function under analysis and signal processing. The Adjacent-
Averaging method was chosen with point of windows of 5. The smoothing calculation 
was only performed on the off peak region of the spectra to preserve the peak feature. 
The rest of the iron spectra shown in this chapter are not processed. 
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! Results 
3.4.1! SXRF results: quantitative analysis from the SXRF map 
The result of the quantification shows that on average the concentration of iron inside 
the cells of SNpc is higher by approximately 3x in control and 1.32x in PD. This result 
in isolation does not match the published result by Oakley et al. (2007) [84]. Although 
the method applied in the paper is not SXRF, the authors also measured the iron counts 
in the cells and the extracellular area/ neuropil in control and PD. Calculating the ratio 
from the results of Oakley et al. (2007) gives the ratio of the average iron counts in the 
cells compared to the extracellular region as 1.5x in control and 1.56x in PD.  
The SXRF analysis shown here does not include sufficient cases to permit a statistical 
analysis, but this approach might be extended to evaluate well-matched sets of cases 
to describe tissue iron distribution at cellular resolution. 
3.4.2! STXM results: identifying a neuromelanin signature 
Figure 3.8a shows the image of the control human brain tissue at the carbon K-edge 
showing the protein tissue structure. The tissue map shows extensive tissue damage 
that is unlikely to be pathological, because this is a control tissue with no known 
neurodegenerative pathology. The likely cause of the extensive tissue damage is the 
sample archiving post-mortem, where large blocks were frozen more slowly than by 
plunge freezing.  
Figure 3.8b shows neuromelanin-like granular structure found in the protein tissue 
shown in figure 3.8a. The process to obtain the granular structure image is described 
in section 3.2.2.2.1. The length of single granules in the structure shown is in the range 
of 200 to 700 nm, which is close to the published value (200- 600 nm) of neuromelanin  
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Figure 3.8 Carbon K-edge STXM protein map from a control (C1) tissue section. Neuromelanin-
like granular structure within the tissue morphology. (a)  Image of the tissue structure taken at the 
protein peak, 288.3 eV. (b) Image of the neuromelanin-like granular structure taken at the carbon 
K-edge energy of 286 eV. At this energy, the tissue structures are not visible. (c) Composite 
image of the area for the two energy map showing the neuromelanin-like granular structure 
localised within the protein structure. The protein structures are in cyan and the neuromelanin-like 
granular structures are in green. 
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Figure 3.9 Images to determine the nature of the neuromelanin-like granular structure (a) 
transmission optical image of the tissue embedded resin on a 100 mesh copper electro-microscope 
grid (black squares surrounding the area). The red arrows point at the dust on the microscope and 
not on the sample. The structures in the blue box is possibly a neuromelanin. (b) The carbon K-
edge STXM protein map taken at 288.3 eV showing the protein structure inside the electron grid 
square. (c) The carbon K-edge STXM protein map taken at 288.3 eV of the area in the blue box in 
(a) and (b). This image is taken at a higher resolution at 125nm. (d) The carbon K-edge STXM 
protein map taken at 286 eV showing the neuromelanin-like granular structure in the same area as 
(c). The shape of the neuromelanin-like granules corresponds to the neuromelanin structure in the 
optical image. (c) and (d) are the same images presented in figure 3.8 (a) and (b), respectively. 
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granules [57]. The composite map composed of the carbon K-edge image mapped at 
288.3 eV (figure 1.10a) and 286 eV (figure 3.8), shows that the neuromelanin -like 
granular structure localised with the protein tissue structure, which may suggest that 
the granules were part of the tissue structure before it disintegrated. This matched with 
the profile of neuromelanin, as it is mainly contained in an organelle in dopaminergic 
cells.  
To further determine if the structure mapped at the carbon K-edge energy 286 eV is 
truly neuromelanin, the carbon image is compared to an optical image of the tissue 
embedded resin of the same section of the same area. Figure 3.9a shows the optical 
image of the tissue embedded resin with a blue box indicating the area with the visible 
neuromelanin structure. Carbon K-edge protein map of the area inside the electron 
microscopy grid is shown in Figure 3.9b. From figure 3.9c and 3.9d, it can be 
determined that area enclosed the blue box in the figure 1.11b is the area where the 
neuromelanin-like granular structure is found at the carbon K-edge energy 286 eV. 
The size of the hole of the (100 mesh) electron microscopy is ~200µm2. From this 
information, it can be deduced that the two blue boxes are indicating the same area. 
Moreover, the structure of the neuromelanin and the proposed neuromelanin-like 
structure are unique, such that it is extremely likely that they are the same structure. 
However, currently this is the only image of the neuromelanin-like structure mapped 
with STXM that can be compared to an optical image, so a definite conclusion on 
whether the carbon K-edge energy 286 eV is specific to neuromelanin structure cannot 
be drawn yet. 
3.4.3! Iron chemistry in control tissue 
The carbon K-edge map at the energy of 288.3 eV in the composite map, shown in 
figure 3.10a is of a different area of the same tissue section as figure 3.8a. The map 
reveals a similar extent of tissue damage that may affect the interpretation of the iron 
deposit location. As in figure 3.8, the composite map also shows neuromelanin-like 
structures localising in the tissue. More images of neuromelanin localising in the 
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Figure 3.10 Iron deposits found within and out of the tissue structures of the control (C1) tissue 
section. (a) Composite map of STXM images of the tissue section at the resolution of 175 nm. The 
protein structures taken at carbon K-edge energy 288.3 eV are in cyan, the neuromelanin-like 
granular structures taken at carbon K-edge energy 286 eV are in green, and the iron deposits taken 
at iron L-edge energy 710 eV are in red. The three iron deposits are shown in a higher resolution 
map 50 nm labelled A, B and C. (A-C) background subtracted image of the iron deposit. (b) Iron 
L-edge X-ray absorption spectra of the three iron deposits comparable to Fe3+ (FeO(OH)) reference 
spectra. Spectra for iron deposits B and C are cut short due to time constraint and they show obvious 
features of Fe3+ peak. The reference spectrum FeO(OH)  was reproduced with permission from Dr 
J. Everett (Everett 2015) [90]. 
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protein tissue structure were found but not shown in this thesis. No iron deposit was 
found in the neuromelanin structure in this tissue, but investigation on the SNpc of 
Alzheimer’s disease brain tissue in parallel work from the group reveals iron deposits 
inside the neuromelanin. 
Multiple areas of iron deposits (red spots) were observed inside and outside the protein 
tissue structure, as shown in figure 3.10a. The iron deposits observed in the control 
human brain tissue are approximately 300 nm in diameter and it does not exhibit any 
complex structure that is observed in the iron deposit of the brain tissue of AD mouse 
brain [103]. The comparison of the iron deposits spectra across the iron L2- and L3-
edge to the Fe3+ reference spectra demonstrate that they are present in a pure ferric 
form. 
3.4.4! Iron chemistry in the PD tissue 
The PD brain tissue investigated here has lost the neuromelanin pigment, so the 
neuromelanin structure observed in the control case cannot be considered directly 
equivalent compared to the neuromelanin measured in the PD case in this thesis. 
Tissue damage is also observed in this tissue, although to a lesser extent than in control 
tissue. It may be caused by the disease pathology or the preservation condition, and 
because of the fragmentation of the tissue, care should still be taken when interpreting 
the location of the iron deposits.  
Carbon K-edge examination of the PD SNpc tissue shows that the iron deposits either 
co-localise directly with protein rich regions in the tissue section, or are adjacent to 
them. The carbon K-edge image is usually insufficient to prove if the iron deposits are 
intra-or extracellular except where cell membranes can be observed. The iron L-edge 
spectra of the iron deposits D and E in figure 3.11b demonstrate an increase in the 
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Figure 3.11 Iron deposits found within and out of the tissue structures of the Parkinson’s disease 
(PD2) tissue section. (a) Composite map of STXM images of the section taken at different energy 
with a resolution of 125 nm. The protein structures taken at carbon K-edge energy 288.3 eV are in 
cyan and the iron deposits taken at iron L-edge energy 710 eV are in red. The neuromelanin is not 
present in this PD tissue. The two iron deposits are shown in a higher resolution map 50 nm labelled 
D and E. (D-E) background subtracted image of the iron deposit. (b) Iron L-edge X-ray absorption 
spectra of the two iron deposits. The iron deposit spectra are compared to Fe3+ (FeO(OH)) and Fe2+ 
(FeCl2) reference spectra. Spectra for iron regions D and E demonstrate an increase intensity of 
the Fe2+ feature at 708 eV (L3 edge) and 721 eV (L2 edge), compared to the Fe3+ reference feature 
at 710 eV (L3 edge) and 723 eV (L2 edge). The reference spectra were reproduced with permission 
from Dr J. Everett (Everett 2015) [90]. 
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Figure 3.12 Iron deposits found within and out of the tissue structures of the Parkinson’s disease 
(PD2) tissue section. (a) Composite map of STXM images of the section taken at different energy 
with a resolution of 125 nm. The protein structures taken at carbon K-edge energy 288.3 eV are in 
cyan and the iron deposits taken at iron L-edge energy 710 eV are in red. The neuromelanin is not 
present in this PD tissue. The two iron deposits are shown in a higher resolution map 50 nm labelled 
F and G. (F-G) background subtracted image of the iron deposit showing complex. The reference 
spectrum was reproduced with permission from Dr J. Everett (Everett 2015) [90]. 
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intensities at the Fe2+ peak features compared to the reference Fe3+ peak. The iron L-
edge spectra of the iron deposits F and G in figure 3.13 has lost the characteristic Fe3+ 
peak at the 710 eV and greatly resembles the zero valent (Fe0) iron reference spectra. 
The zero valent form of iron is not commonly found in the measurement of biological 
materials, and its finding in amyloid plaque cores has only been recently reported by 
our group [105]. Ferrous and zero valent spectral contribution were not observed in 
the iron deposits sampled in the control. 
  
 
 
Figure 3.13 Iron L-edge X-ray absorption spectra of the two iron deposits. The iron deposit spectra 
are compared to zero valent iron (Fe0) reference spectra. Spectra for iron regions D and E 
demonstrate a resemblance to spectra feature that is close to Fe0 spectra. The reference spectrum 
was reproduced with permission from Dr J. Everett (Everett 2015) [90]. 
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! Discussion 
3.5.1! SXRF iron quantification  
SXRF mapping has been widely used in the quantification of metal contents in tissue 
sections, however, few studies have been published on its application on quantifying 
the iron content in cells and comparing it to the neuropil [106, 107]. Therefore, the 
purpose of the SXRF measurement in this chapter is to show the use of cutting edge 
techniques to investigate the relation of iron in disease. In the future, the result from 
these measurements can be applied to fit a computational model that represents the 
disease condition better or to validate the computational model in chapter 5.  
The SXRF mapping in this thesis is for illustration purposes only, and the number of 
samples required for a detailed comparison might be estimated from prior single point 
microprobe studies, for example Oakley et al. (2007) [84].   
3.5.2! STXM tissue mapping spectra from iron deposits 
This thesis is the first to report possible energy at the carbon K-edge that is specific to 
neuromelanin. 
The neuromelanin structure observed in the optical image of the resin, and the 
candidate neuromelanin granular structure that is mapped at 286 eV, strongly resemble 
each other. The size of the two structures is also similar. The finding of an energy peak 
that is specific to neuromelanin that can be applied to STXM would improve the way 
the compartmentalisation of the iron deposits in the neuromelanin and its oxidation 
state, can be studied. The methods that have currently been applied to study the iron 
deposits in the neuromelanin only allow the measurement or observation of the iron in 
the neuromelanin containing dopaminergic neurones, not specifically the 
neuromelanin granules. Using this energy, 286 eV, at the carbon K-edge to determine 
the neuromelanin, will allow the determination of the spatial distribution of the iron in 
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the neuromelanin and the oxidative states of the iron deposits. Detailed investigation 
of iron-neuromelanin relationships by STXM was beyond the scope of this thesis. 
The iron L-edge x-ray absorption spectra of the iron deposits reveal ferrous iron 
deposits found in PD tissue that is not apparent in the control tissue. The iron deposits 
found in control tissues are in the form of pure ferric iron. Ferric iron in biological 
systems is mostly bound to the iron transporter, transferrin, or stored in the core of 
iron storage protein, ferritin. This bound ferric iron is stable and does not usually 
become involved in the production of reactive oxygen species (ROS). Therefore, this 
is consistent with iron being stored in the expected form.  
The iron L-edge x-ray absorption spectra of the iron deposits F and G demonstrate the 
presence of zero valent iron (Fe0) in the PD tissue. The finding of zero valent iron 
state is not common. Everett et al. (2018) was the first to report the evidence of its 
presence in human amyloid plaque cores [105], and to the best of our knowledge this 
is the first observation of zero valent iron in PD tissue. The spectrum for Fe0 is easily 
distinguishable by the broader peak and the lacks of multiple fine structures. The zero 
valent iron findings are less likely to result from artefacts or contaminations during 
sample preparation, because no iron containing instruments were used in the process. 
The effect of prolonged exposure of x-ray on the iron has also been studied extensively 
and found that the x-ray beam does not chemically reduce the iron deposits in unstable 
aggregates even after repeated scans [90, 108]. 
While these findings show the power of STXM to reveal important information about 
iron in on PD, STXM only allows measurement of postmortem subjects (human/ 
animal models). The results from these methods will not reveal the dynamics of the 
disease progression, for example, the time it takes for iron to accumulate in the disease 
state. To address this, chapter 4 and 5 present the development of a computational 
model to be used as another effective tool to explore the role of iron in the brain, and 
to study dynamics of the iron uptake into the brain and dopaminergic neurone in health 
and disease (PD). 
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The published paper coming from collaborative work referred to in this chapter are 
included in Appendix E and F, and are as follows: 
J. Everett, V. T. Tjhin, J. Brooks, F. Lermyte, I. Hands-Portman, J. Dobson, J. 
Collingwood, and N. Telling, “Nanoscale Examination of Biological Tissues Using 
X-ray Spectromicroscopy,” Microscopy and Microanalysis, vol. 24, no. S2, pp. 490–
491, 2018. 
Everett, James, Joanna F. Collingwood, Vindy Tjendana-Tjhin, Jake Brooks, Frederik 
Lermyte, Germán Plascencia-Villa, Ian Hands-Portman, Jon Dobson, George Perry, 
and Neil D. Telling. "Nanoscale synchrotron X-ray speciation of iron and calcium 
compounds in amyloid plaque cores from Alzheimer's disease 
subjects." Nanoscale (2018). 
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In chapter 3, we observed the capability of the synchrotron X-ray fluorescence to 
calculate the relative concentration of iron in the cell to the neuropil, and also the 
duality of scanning transmission X-ray microscopy, being capable of producing a high 
spatial resolution image of iron localisation in the tissue and determining the oxidative 
state of the iron. These are powerful techniques, however, they allow only to the 
investigation of iron in the post-mortem brain tissue. These data are the concentration 
of iron at one time point. The dysregulation of iron in Parkinson’s disease (PD) has 
been observed for decades [2, 16, 109]. The accumulation of iron in this area has been 
linked to the death of cells in the tissue, but how this accumulation occurs and affect 
the disease progression is still not well understood [110, 111]. In this chapter, a 
computational model of the iron uptake in the brain is presented, which would provide 
an in silico qualitative and quantitative tool to explore the complex network of brain 
iron metabolism.  
This chapter presents a computational model that has been developed from an initial 
concept by Drs J.F. Collingwood and S. Mitchell [112],which attempts to characterise 
iron transport in and out of the brain. The model concept was already well-developed 
with the majority of the reactions included at the outset of this PhD research. The 
initial work done was to fully understand and test the model, and to simulate 
alternative pathways, and determine if additional reactions were needed. The original 
contribution described in this chapter arises from this development and testing work, 
Chapter 4! Modelling brain iron metabolism in 
the barrier systems 
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and this unique model is the subject of a manuscript intended for joint publication 
including Drs J.F. Collingwood and S. Mitchell1. 
The iron in the blood and the brain is separated by the brain barrier system, the blood 
brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCB). Figure 4.1 
illustrates the direction of flow of iron across these barriers and the full schematics of 
the uptake of iron into the brain adapted in the model. The additional complexity of 
the transport of iron into the dopaminergic (DA) neurone, one of the main cell affected 
in PD, is explored in chapter 5. 
! Iron uptake in the brain background 
The brain receives iron from the blood circulation, but this uptake is not unrestricted 
[75]. The content of the brain is separated from the body by two barriers: the blood 
brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCB). The BBB is 
formed by the brain capillary endothelial cells (BCECs) and separates the blood and 
the interstitial fluid (ISF) in the brain. The BCB is comprised of the epithelial cells of 
the choroid plexus in the brain ventricles and separates the blood from the 
cerebrospinal fluid (CSF) in the brain ventricles. The major flow of iron across these 
barriers is shown conceptually in figure 4.1. The cells in the BBB and the BCB are 
connected by tight junctions that prohibit the free exchange of iron between the brain 
and the body, thus iron has to be transported by a receptor mediated transport 
mechanism [113]. Transferrin receptors (TfRs) are on the luminal side of the BBB and 
the apical and abluminal side of BCB. TfRs bind with available transferrin-bound iron 
(Tf-Fe) and this initiates its endocytosis into the cells. Ferrireductase, such as six-
transmembrane epithelial antigen of the prostate 3 (STEAP3) and divalent metal 
transporter 1 (DMT1), release the iron from the endosome into cell cytosol, creating 
the labile iron pool (LIP). The presence of DMT1 at the surface of the BBB recently$
                                                
1 Intended for submission to: Journal of Cerebral Blood Flow and Metabolism 
 
55 
 
started$to$be$recognised [49]. In BCB, DMT1 is predominantly distributed on the 
apical surface of the BCB. The polarised distribution of DMT1 may indicate the 
dominant direction of iron flow in the BCB. Iron in the LIP is in a Ferrous (Fe2+) state 
and is available to be taken up by and stored in ferritin, an iron storage protein, or to 
be transported out of the cell by ferroportin. Iron response proteins (IRPs) in the BBB 
post-transcriptionally regulate the expression of the TfR, DMT1, ferritin and 
ferroportin in the cells. In the liver, hepcidin regulates the degradation of ferroportin. 
The presence of hepcidin protein in this region has also been shown by several authors 
[73], but the translation of hepcidin in the brain is well known [74]. The model in this 
chapter disregards another hypothesis that states that systemic Tf-Fe3+ crosses the BBB 
and enters the ISF, as well as non-Tf-Fe transport, because it is commonly accepted 
that Tf-FE is the primary species transported into the brain, where less than 1% of iron 
is in blood is unbound [7]. 
Once iron has crossed the BBB into the ISF, most of the iron is carried by brain 
transferrin (Tf) for neuronal activities. Excess iron in brain cells returns back to the 
ISF and is released into the CSF in the brain ventricles through bulk flow. The cells 
separating the ISF and the CSF are fenestrated allowing free exchange of iron between 
these compartments. 
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Figure 4.1 (A) Illustration of the flow of iron between the blood and the brain. The fenestrated cells 
between the ISF and the CSF allow free exchange of iron, but the direction of the fluid bulk flow 
is principally from the ISF into the CSF. The arrow represents the direction of the iron transport 
and the dotted arrow represents the weaker flow of Tf-Fe from ISF to CSF. (B) Conceptual 
biological diagram for iron uptake in the brain that the model in this chapter derived from. 
Abbreviations: BBB: blood brain barrier, BCB: blood cerebrospinal fluid, BCEC: brain capillary 
endothelial cell (comprises the BBB), CPEC: choroid plexus epithelial cell (comprises the BCB), 
CSF: cerebrospinal fluid, DMT1: divalent metal transporter 1, Fe: iron, Fpn: ferroportin, Ft: 
ferritin, Hepc: hepcidin, IRP: iron response protein, ISF: interstitial fluid, LIP: labile iron pool, Tf: 
transferrin, Tf-Fe: transferrin bound iron, TfR: transferrin receptor. 
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! Materials and methods 
The model is constructed, simulated and analysed using COPASI, a generic software 
package for biochemical system modelling [5]. The system biology graphical notation 
(SBGN) process diagram (figure 4.2) for the model was derived from figure 4.1 and 
created using Cell Designer [114]. Five compartments were constructed, representing 
the blood, the BBB, the interstitial fluid (ISF), the cerebrospinal fluid (CSF), and the 
BCB. The ISF surrounds the brain and provides iron for cells in the brain, so it 
represents the ‘brain’ compartment in this chapter. The volumes of these 
 
Figure 4.2 Systems Biology Graphical Notation (SBGN) process diagram of iron trafficking in the 
human brain barrier system model based on the mechanistic representation of the biological system 
shown in figure 4.1. Complexes are represented in boxes with component species. In the special 
case of the ferritin-iron complex symbol, the amounts of each species are not in stoichiometric 
amounts (there are thousands or iron ions per ferritin). Species overlaid on the compartment 
boundaries represent membrane-associated species. Abbreviation: BBB: blood brain barrier, BCB: 
blood cerebrospinal fluid, CSF: cerebrospinal fluid, DMT1: divalent metal transporter 1, Fe: iron, 
Fpn: ferroportin, Ft: ferritin, IRP: iron response protein, LIP: labile iron pool, Tf-Fe Serum: 
transferrin bound iron in the blood plasma, TfR: transferrin receptor. 
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compartments are listed in table 4-1. The corresponding volumes of the BBB and the 
BCB were derived by multiplying the total brain volume, 1400 ml, by the percentage 
of brain endothelial cells (BCECs) (0.2%) to give 2.8 ml [115, 116].  
Table 4-1 Volume of model compartments 
Compartment Volume (l) Source 
Blood serum 0.15 human [115] 
Blood brain barrier (BBB) 0.0028 human [115, 
116] 
Blood cerebrospinal fluid barrier 
(BCB) 
0.0028 human [115, 
116] 
Interstitial fluid (ISF) 0.025 human [117] 
Cerebrospinal fluid (CSF) 0.15 human [115] 
 
Fe3+ binds strongly to Tf with an affinity constant, Ka, of 1022 M-1[118], the Kon of the 
binding is 1020.2 M-1 s-1[119]. The off rate for the reverse reaction (Ka = Kon/Koff) is very 
small, 0.0158 s-1. Therefore, it was assumed that all iron arriving in the brain capillaries 
is of the form of Tf-FE and the iron arriving at the ISF immediately binds to available 
empty Tf (apo-Tf) produced by neighbouring cells. The binding of iron to Apo-Tf was 
not considered in this model in order to avoid unnecessary complexity and also due to 
the high affinity of Apo-Tf to iron [39]. The concentration of Tf-Fe in the serum was 
fixed to represent the constant influx of iron from the liver. The concentration of 
hepcidin in both the BBB and the BCB was also fixed to represent hepcidin received 
from the liver. Hepcidin is mainly expressed in the liver and although this protein has 
been found in the brain, its translation in the brain is still not well established. It has 
been speculated that the hepcidin protein received in the brain is derived from the liver 
[73], thus the concentration of hepcidin is fixed in this model. The value of the 
concentration applied in this model was taken from the steady state simulation of 
hepcidin using the hepatocyte iron model built by Mitchell (2013) [120]. The initial 
concentrations of the metabolites were fixed to appropriate concentrations based on a 
literature survey, and for metabolites that go through a complex binding process, their 
initial concentrations were set to zero (table4-2).  
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Table 4-2 Initial concentration of all metabolites 
Metabollites Initial concentrations (M) Source 
Tf-Fe_Serum 5 x 10-6 (fixed) human 
[121] 
TfR_BBB 0  
TfR_BBB-Tf-Fe 0  
TfR_BBB-2(Tf-Fe) 0  
Endo_Fe3+_BBB 0  
Endo_Fe2+_BBB 0  
LIP_BBB 0  
IRP_BBB 0  
Fpn_BBB 0  
Fe-ferritin_BBB 0  
Ferritin_BBB 2 x 10-10 in silico 
[94, 122] 
Fe_within_ferritin_BBB 7 x 10-15  
Hepcidin_BBB 5 x 10-9 (fixed) in silico 
[120] 
DMT1_BBB 0  
Tf-Fe_ISF 0  
TfR_BCB-Tf-Fe_CSF 0  
TfR_BCB-2(Tf-Fe) 0  
Tf-Fe_CSF 0  
TfR_BCB 0  
IRP_BCB 0  
Endo_Fe3+_BCB 0  
Endo_Fe2+_BCB 0  
LIP_BCB 0  
Hepcidin_BCB 5 x 10-9 (fixed) in silico* 
[120] 
Ferritin_BCB 2 x 10-10 in silico* 
[94, 122] 
Fe_within_ferritin_BCB 7 x 10-15  
Fe-ferritin_BCB 0  
Fpn_BCB 0  
DMT1_BCB 0  
* in silico model of human condition 
The model presented in this chapter was adapted from the human iron metabolism 
model developed by Mitchell et al. (2013) [94]. The model is built using ordinary 
differential equations (ODEs) to represent the rate of changes of each chemical 
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species. In cases where there is no evidence that the synthesis and degradation rate or 
binding rate of a certain metabolite is different in the brain than in the liver, they are 
therefore assumed to be the same. The equations applied to the computational model 
are explained in the following paragraphs, but reactions modelled using the same 
equation are not explained in detail. The full set of the reactions in the model are listed 
together with their corresponding functions and parameter values are listed in table 4-
3. The full set of equations is given in Appendix A.  
The degradation rates of the proteins were calculated using the following equation: 
;< =
=>2
@A
B
 
where, kd is the degradation rate constant and T1/2 is the half-life of the relevant protein 
gathered from published literature. The degradation rate then can be used together with 
estimated steady-state concentration from the literature to compute the synthesis rate 
using the equation: 
![D]
!#
= ;2 − ;< D = 0 
where, [P] is the concentration of the protein, ks is the synthesis rate and kd is the 
degradation rate constant. The steady state concentration of the protein [D] is given 
by: 
D = +
;2
;<
 
The half-life of transferrin receptor (TfR) was shown to be ~23 hours in [121] and the 
number of TfRs on the cell surfaces was shown to be 35000 TfRs per cell [123], which 
is 10 times lower than the number of TfRs in the liver cells [42, 124]. The degradation 
rate of TfRs in the BBB was calculated and the expression rate of the cell was adjusted 
to a value 10 times lower than the expression rate in the liver. The degradation and 
Eq. 4.1 
Eq. 4.2 
Eq. 4.3 
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expression rates of the remainder of the proteins were obtained using equations 4.1 
and 4.2. 
The reaction for the complex formations, such as the binding of two Tf-Fe serum 
molecules to TfR on the BBB and the BCB surfaces, was modelled using the on and 
off rate constants for the appropriate reversible mass action. The example below is the 
reaction for the binding of the first Tf-Fe serum to the TfR: 
@HIJJJ + @L − HM2-,NO ↔ @LIJJJ − @L − HM 
This reversible reaction was modelled using two irreversible mass action reactions: 
@HIJJJ + @L − HM2-,NO
QR
@LIJJJ − @L − HM 
@LIJJJ − @L − HM
QS
+@HIJJJ + @L − HM2-,NO  
where, ka is the association rate and kd is the dissociation rate. The ODEs 
corresponding to these kinetic reactions are given by:  
![@LIJJJ]
!#
= −;) @LIJJJ @L − HM2-,NO
+ ;< @LIJJJ − @L − HM2-,NO +⋯ 
! @L − HM2-,NO
!#
= −;) @LIJJJ @L − HM2-,NO  
+;< @LIJJJ − @L − HM2-,NO +⋯  
! @LIJJJ − @L − HM2-,NO
!#
= +;) @LIJJJ @L − HM2-,NO  
−;< @LIJJJ − @L − HM2-,NO +⋯  
Once the second Tf-Fe bound to TfRBBB-Tf-Feserum, the complex TfRBBB-2(Tf-Feserum) 
enters the endosome in the cytosol of the BBB and the BCB, the four iron molecules 
that were bound to Tf are released and reduced into Fe2+. Then the four reduced Fe2+ 
Eq. 4.4 
Eq. 4.5 
Eq. 4.6 
Eq. 4.7 
Eq. 4.8 
Eq. 4.9 
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molecules are transported out of the endosome into the cytosol of the BBB by divalent 
metal transporter 1 (DMT1). Both iron reduction and iron endosomal export reactions 
follow Henri-Michaelis-Menten kinetics, namely: 
( = UO)V
[W]
W XYZ
  
where, 
UO)V = ;[\#×[^] 
and where, υ is the reaction rate, [S] is the concentration of the substrate, [M] is the 
concentration of the modifier, Vmax is the reaction’s maximal rate, kcat is the catalyst 
rate constant and Km is the Michaelis constant, i.e. concentration of ligand producing 
half occupancy of the enzyme binding sites. In cases where Km is not known, it has 
been estimated to be of the order of magnitude of the experimentally observed ligand 
concentration. 
As mentioned in section 2.2.2, the binding of iron response protein (IRP) to the iron 
response element (IRE) at the 3’ untranslated region (UTR) of the target mRNAs leads 
to stability and expression of the proteins, such as in TfR and DMT1. This reaction is 
represented by Hill kinetics in equation 3.11. The binding of IRP to the IRE at 5’ UTR 
of the target mRNAs causes reduced translation rate, such as in the expression of 
ferritin and ferroportin. This is represented by equation 3.12, as follows.  
( = [_]×\
[^]1
`1 + [^]1
 
( = [_]×\ 1 −
[^]1
`1 + [^]1
 
where, υ is the reaction rate, S is the substrate, M is the modifier, K is the concentration 
of ligand producing half occupancy of the enzyme binding sites, a is the turnover 
number, and n is the Hill coefficient. When the value of n is equal to 1, the resulting 
response is equivalent to Henri-Michaelis-Menten kinetics. When n is larger than 1, it 
produces a positive cooperativity response, and when n is smaller than 1, it produces 
Eq. 4.10 
Eq. 4.11 
Eq. 4.12 
Eq. 4.13  
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a negative cooperativity response. The Hill coefficient was assumed to be 1 unless 
contradictory evidence was found. The degradation of ferroportin by hepcidin and the 
export of iron by ferroportin were also simulated using the Hill kinetics as per equation 
3.11.  
The binding of iron from the labile iron pool (LIP) to ferritin and its internalisation 
were modelled using mass action kinetics. The release of iron from ferritin was 
modelled using equations that Mitchell et al. (2013) [94] adapted from Salgado et al. 
(2010) [125]. There are two ways that iron internalised in ferritin can be released:  
1.! Ferritin releasing iron through its pores 
2.! Degradation of ferritin leading to the release of all the iron inside the ferritin.  
The first iron release reaction is affected by the average amount of iron stored inside 
the ferritin. The equation for ferritin releasing iron through its pores is given by [94]: 
( = [_]×;*022 1 +
9.9cd
[efg]
[ef]
AX
[efg]
[ef]
  
where υ is the reaction rate, S is the internalised iron, kloss is the rate constant and 
FT1/FT is the ratio of iron in the ferritin to the total ferritin protein available. The 
kinetics of iron release due to whole ferritin degradation is based on irreversible mass 
action, but the amount of iron released is an average of the ferritin levels and the total 
iron internalised in the ferritin. This gives the equation for [120]:  
( = [_]×;<×
[H@1]
[H@]
 
where υ is the reaction rate, S is the internalised iron, kd is the degradation rate constant 
and FT1/FT is the ratio of iron in the ferritin to total ferritin protein available. 
Eq. 4.14 
3.10 
Eq. 4.15 
3.10 
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In order to analyse the sensitivity of the model metabolites to the reactions, the 
metabolic control analysis calculation was performed using COPASI, using equation 
[98, 99]:  
hij
k =
lm
lU&
U&
m
 
where, A is the variable in the system, either concentrations or fluxes and Vi is the 
reaction rate.   
Eq. 4.16 
3.10 
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Table 4-3 Reactions involved in the iron transport in the barriers and their parameters 
Name Reaction Function  Parameters Ref 
TfR_BBB 
expression 
→ TfR BBB; IRP BBB Hill function → 
a = 2 x 10-12 s-1,  
n = 1, 
K = 1x 10-6 mol 
[123, 
124] 
TfR_BBB 
degradation 
TfR BBB → Mass action (irreversible) k = 8.37 x 10 -6 s-1 [124] 
TfR_BBB binding 1 TfR_BBB + Tf-Fe_serum → TfR_BBB-Tf-Fe_serum Mass action (irreversible)  k = 837400 l*(mol*s)-1 [42] 
TfR_BBB release 1 TfR_BBB-Tf-Fe_serum → TfR_BBB + Tf-Fe_serum Mass action (irreversible) k = 9.142 x10-4 s-1 [42] 
TfR_BBB binding 2 TfR_BBB-Tf-Fe_serum + Tf-Fe_serum → 2(Tf-Fe)-TfR_BBB Mass action (irreversible) k = 121400 l*(mol*s)-1 [42] 
TfR_BBB release 2 2(Tf-Fe)-TfR_BBB → TfR_BBB-Tf-Fe_serum + Tf-Fe_serum Mass action (irreversible) k = 3.535 x10-3 s-1 [42] 
TfR_BBB iron 
internalisation 
2(Tf-Fe)-TfR_BBB ↔ 4 * endoFe3_BBB + TfR_BBB Mass action (reversible) 
k1 = 0.8333 s-1  
k2 = 0.1 l5*(mol4*s)-1 
[42] 
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Name Reaction Function  Parameters Ref 
Steap3_BBB iron 
reduction 
endoFe3_BBB → endoFe2_BBB Henri-Michealis-Menten  
Km = 7.4 x10-5 mol*l-1 
V = 1.493 x10-4 mol (l*s)-1 
[94] 
DMT1_BBB 
expression 
→ DMT1_BBB;  IRP_BBB Hill function → 
a = 1.39 x10-10 s-1 
n = 1  
K = 2.5x10-6 mol 
[94] 
DMT1_BBB 
degradation 
DMT1_BBB → Mass action (irreversible) k = 2.4x10-5 s-1 [94] 
DMT1_BBB 
endosomal export 
endoFe2_BBB → LIP_BBB;  DMT1_BBB Henri-Michealis-Menten  
kcat = 258.6 s-1  
Km = 4.8 x10-6 mol*l-1 
[94] 
IRP_BBB 
expression 
→ IRP_BBB;  LIP_BBB Hill Function -| 
a = 4x10-11 mol*(l*s)-1  
n = 1  
K = 1x10-7 mol 
[47] 
IRP_BBB 
degradation 
IRP_BBB → Mass action (irreversible) k = 1.597 x 10-5 s-1 [126] 
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Name Reaction Function  Parameters Ref 
Fpn_BBB 
expression 
→ Fpn_BBB;  IRP_BBB Hill function -| 
a = 1x10-9 mol*(l*s)-1 
n = 1 
K = 1x10-7 mol 
[94] 
Fpn_BBB 
degradation 
Fpn_BBB →;  Hepcidin_BBB 
Biochemical hill function 
→ 
a = 2.315x10-4 mol*(l*s)-1  
n = 5 
K = 5x10-9 mol 
[94] 
Fpn_BBB export 2 * LIP_BBB ↔ Tf-Fe_ISF;  Fpn_BBB 
Biochemical hill function 
→ 
a = 2 mol*(l*s)-1 
n = 1 
K = 3x10-6 mol 
[127] 
Temporary Tf-
Fe_ISF use 
Tf-Fe_ISF → Mass action (irreversible)  k = 5 x10-5 s-1  
Ferritin_BBB 
expression 
→ Ferritin_BBB;  IRP_BBB Hill function -| 
a = 2.312x10-13 mol*(l*s)-1 
n = 1 
[122] 
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Name Reaction Function  Parameters Ref 
K = 1x10-6 mol 
Ferritin_BBB 
degradation 
Ferritin_BBB → Mass action (irreversible) k = 1.203 x 10-5 s-1 [125] 
Ferritin_BBB full 
degradation iron 
release 
Fe_within_ferritin_BBB → LIP_BBB;  Fe_within_ferritin_BBB 
Ferritin_BBB 
Mass action ferritin k = 1.203 x 10-5 s-1 [125] 
Ferritin_BBB 
internalised iron 
release 
Fe_within_ferritin_BBB → LIP_BBB;  Fe_within_ferritin_BBB 
Ferritin_BBB 
Kloss Hill kloss = 13.1251 s-1 [125] 
Ferritin_BBB iron 
binding 
LIP_BBB + Ferritin_BBB → Fe-ferritin_BBB Mass action (irreversible) k = 4.71 x 1010 l*(mol*s)-1 [125] 
Ferritin_BBB iron 
internatlisation 
Fe-ferritin_BBB → Fe_within_ferritin_BBB + Ferritin_BBB Mass action (irreversible) k = 108000 s-1 [125] 
Ferritin_BBB iron 
release 
Fe-ferritin_BBB → LIP_BBB + Ferritin_BBB Mass action (irreversible) k = 22922 s-1 [125] 
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Name Reaction Function  Parameters Ref 
Flow of Tf-FE 
between ISF and 
CSF 
Tf-Fe_ISF ↔ Tf-Fe_CSF Mass action (reversible) 
k1 = 100 s-1  
k2 = 100 s-1 
 
TfR_BCB 
expression 
→ TfR_BCB_apical;  IRP_BCB Hill Function → 
a = 2 x 10-12 s-1 
n = 1 
K = 1x 10-6 mol 
[123, 
124] 
TfR_BCB 
degradation 
TfR_BCB_apical → Mass action (irreversible) k = 8.37 x 10 -6 s-1 [124] 
TfR_BCB binding 1 TfR_BCB_apical + Tf-Fe_CSF → TfR_BCB-Tf-Fe_CSF Mass action (irreversible) k = 837400 l*(mol*s)-1 [42] 
TfR_BCB release 1 TfR_BCB-Tf-Fe_CSF → TfR_BCB_apical + Tf-Fe_CSF Mass action (irreversible) k = 9.142 x10-4 s-1 [42] 
TfR_BCB binding 2 TfR_BCB-Tf-Fe_CSF + Tf-Fe_CSF → 2(Tf-Fe)-TfR_BCB Mass action (irreversible) k = 121400 l*(mol*s)-1 [42] 
TfR_BCB release 2 2(Tf-Fe)-TfR_BCB → TfR_BCB-Tf-Fe_CSF + Tf-Fe_CSF Mass action (irreversible) k = 3.535 x10-3 s-1 [42] 
TfR_BCB iron 
internalisation 
2(Tf-Fe)-TfR_BCB ↔ 4 * endoFe3_BCB + TfR_BCB_apical Mass action (reversible) 
k1 = 0.8333 s-1  
k2 = 0.1 l5*(mol4*s)-1 
[42] 
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Name Reaction Function  Parameters Ref 
Steap3_BCB iron 
reduction 
endoFe3_BCB → endoFe2_BCB Henri-Michaelis-Menten 
Km = 7.4 x10-5 mol*l-1 
V = 1.493 x10-4 mol (l*s)-1 
[94] 
DMT1_BCB 
expression 
→ DMT1_BCB;  IRP_BCB Hill function → 
a = 1.39 x10-10 s-1 
n = 1 
K = 2.5x10-6 mol 
[94] 
DMT1_BCB 
degradation 
DMT1_BCB → Mass action (irreversible) k = 2.4x10-5 s-1 [94] 
DMT1_BCB 
endosomal export 
endoFe2_BCB → LIP_BCB;  DMT1_BCB Henri-Michealis-Menten  
kcat = 258.6 s-1 
Km = 4.8 x10-6 mol*l-1 
[94] 
Fpn_BCB 
expression 
→ Fpn_BCB;  IRP_BCB Hill function -| 
a = 1x10-9 mol*(l*s)-1 
n = 1 
K = 1x10-7 mol 
[94] 
Fpn_BCB 
degradation 
Fpn_BCB → ;  Hepcidin_BCB Biochemical hill function a = 2.315x10-4 mol*(l*s)-1 [94] 
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Name Reaction Function  Parameters Ref 
n = 5 
K = 5x10-9 mol 
Fpn_BCB export 2 * LIP_BCB ↔ Tf-Fe_serum;  Fpn_BCB Biochemical hill function 
a = 2 mol*(l*s)-1 
n = 1 
K = 3x10-6 mol 
[127] 
IRP_BCB 
expression 
→ IRP_BCB;  LIP_BCB Hill function -| 
a = 4x10-11 mol*(l*s)-1 
n = 1 
K = 1x10-7 mol 
[47] 
IRP_BCB 
degradation 
IRP_BCB → Mass action (irreversible) k = 1.597 x 10-5 s-1 [126] 
Ferritin_BCB 
expression 
→ Ferritin_BCB;  IRP_BCB Hill function -| a = 2.312x10-13 mol*(l*s)-1 
n = 1 
K = 1x10-6 mol 
[122] 
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Name Reaction Function  Parameters Ref 
Ferritin_BCB 
degradation 
Ferritin_BCB → Mass action (irreversible) k = 1.203 x 10-5 s-1 
[125] 
Ferritin_BCB full 
degradation iron 
release 
Fe_within_ferritin_BCB → LIP_BCB;  Fe_within_ferritin_BCB 
Ferritin_BCB 
Mass action ferritin k = 1.203 x 10-5 s-1 
[125] 
Ferritin_BCB 
internalised iron 
release 
Fe_within_ferritin_BCB → LIP_BCB;  Fe_within_ferritin_BCB 
Ferritin_BCB 
Kloss Hill kloss = 13.1251 s-1 
[125] 
Ferritin_BCB iron 
binding 
LIP_BCB + Ferritin_BCB → Fe-ferritin_BCB Mass action (irreversible) k = 4.71 x 1010 l*(mol*s)-1 
[125] 
Ferritin_BCB iron 
internalisation 
Fe-ferritin_BCB → Fe_within_ferritin_BCB + Ferritin_BCB Mass action (irreversible) k = 108000 s-1 
[125] 
Ferritin_BCB iron 
release 
Fe-ferritin_BCB → LIP_BCB + Ferritin_BCB Mass action (irreversible) k = 22922 s-1 
[125] 
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! Model simulation results 
A novel mathematical model of iron kinetics and transport between the blood and the 
brain across the brain barrier systems was presented in this chapter. To my knowledge, 
this is the first computational model of the iron transport across the brain barriers that 
incorporated the regulatory of the expression of TfR, DMT1, ferroportin and ferritin 
by IRP.  The model in Systems Biology Markup Language (SBML) and COPASI 
format will be provided in the BioModels database in due course. 
Figure 4.1 shows the biological diagram of brain iron trafficking that was adapted into 
the model and figure 4.2 depicts the process diagram of the model using the Systems 
Biology Graphical Notation (SBGN) standard [128]. The kinetics for each chemical 
species in the transport of iron in this model are characterised by nonlinear ordinary 
differential equations (listed in the appendix A)  
Experimentally determined model parameter values for compartmental volumes, 
initial species concentrations, and rate constants for each species were extracted from 
the literature. Parameter estimation was not performed during model construction due 
to lack of available data. The accurate representation of the underlying protein 
dynamics allows the model to recreate qualitatively, rather than quantitatively, 
experimental observations. The accurate representation of the underlying protein 
dynamics allows the model to recreate experimental observation accurately. The work 
detailed here provides an extremely useful test bed for testing the dynamics of iron 
transport to and from the brain in response to various systemic serum iron levels. 
4.3.1! Transferrin-transferrin receptor binding 
Simulated transferrin receptor levels were found to be consistent with experimental 
concentrations. Serum iron in normal human blood exists primarily in the form of Fe3+ 
bound to Tf, so TfR is the primary importer of iron into the brain. The expression rate 
of TfR in the BBB is ten times lower than in the liver under normal conditions. The 
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model steady state simulation gives a prediction of 30050 TfRs per cell which is close 
to the value of 35000 previously published in Descamps (1996) [123]. This value is 
much lower than for other cell types [129].  
 To further confirm the appropriateness of the model, simulation results were 
compared to published experimental data. The transferrin receptor binding curve, 
shown in figure 4.3, was generated by plotting the steady state concentration of 
transferrin bound to its receptors as increasing doses of Tf-Fe are added into the serum 
compartment of the model. The values have been normalised by dividing all 
concentrations by the highest concentration value in the simulation and experimental 
 
Figure 4.3 Transferrin – Transferrin Receptor binding curve, showing saturating of iron binding to 
BBB cells as seen in the experimental data with rat brain slices from Hill et al. (1985) [130]. Both 
simulation and experimental data share the same y-axis. The top axis is for the simulation data and 
the bottom axis is for the experimental data. The model was not fitted to these data. 
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results, respectively. This was done because the magnitude of the concentrations from 
the two different systems (simulated human brain and rat brain) are not expected to be 
similar. The simulated curve shows that the binding of transferrin-bound iron to the 
transferrin receptor does not depend linearly on the concentration of transferrin-bound 
iron available and that the process is saturable. The saturating kinetics resemble the 
experimentally derived binding curve for increasing concentration of 125I-Tf to the TfR 
in rat brain slice performed on rat brains by Hill et al. (1985) as shown in figure 4.3 
[130]. As the experimental results were acquired from a fraction of rat brains, the result 
is not comparable, quantitatively. However, the simulation result still shows a 
qualitative similarity to the dynamics of the experiment-derived binding curve. 
4.3.2! Iron uptake across the blood brain barrier 
 Another comparison to experimental data performed was the simulation of the 
dynamics of the Tf-Fe concentration in the ISF following a virtual injection of Tf-Fe 
in the serum. The simulated curve shows a similar qualitative trend as that of the 
experimental result of Tf uptake performed by Taylor and Morgan (1990) [131] (figure 
4.4). In the simulation, the addition of Tf-Fe to the serum in a virtually iron starved 
model results in an abrupt increase of Tf-Fe in the ISF. The concentration reaches a 
peak at around 1 hour and is then maintained until it decreases rapidly after ~7 hours. 
This trend is similar to that observed in the results of experimental studies [131] on 
the uptake of Tf by the rat brain after injection of 125I-59Fe-Tf. The values in the graph 
have also been normalised such that the largest value is 1 and the smallest value is 0 
for both the simulation and experimental results, respectively, to account for the 
different concentration magnitude that would be observed between the two systems 
(i.e. simulated human system and rat brain system). The value of chi squared value for 
the two qualitatively fitted data sets is approximately 0.04. 
 
76 
 
The model was used to examine the impact of constant high iron concentration, higher 
than ~20 µM which is the normal serum iron concentration [14, 132], on the uptake of 
iron across the barriers, as shown in figure 4.5. The rate of iron uptake from the blood 
serum into the brain interstitial fluid quickly increases over the first couple of days, as 
shown in figure 4.5A. The higher the concentration of the serum iron the faster Tf-Fe 
uptake reaches its maximum rate. However the rate is tightly constrained to never 
exceed 0.12uM/s even in extreme system iron loads. The concentration of LIP in the 
BBB and the BCB in response to iron overload is shown in figure 4.5B. The simulated 
LIP concentrations in both the BBB and the BCB reach steady state faster with 
increasing concentration of Tf-Fe in serum, however the steady state concentration of 
the LIP is unchanged (~0.13µM) when the Tf-Fe serum concentration is higher than 
 
Figure 4.4 Semi-log plot of the time course of Tf-Fe Uptake across the BBB following an iron 
injection event. The simulation result shows similar dynamics for iron influx and subsequent 
outflow following radio-labelled iron injection compared to the study undertaken by Taylor and 
Morgan 1990 [131] on rat brains. The model was not fitted to these data. To confirm the model 
appropriateness we compared uptake dynamics with a simulation representing iron injection. 
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20 µM. Iron does not build-up in the LIP of the BBB and the BCB even for extreme 
iron loads. The concentration of the LIP (<0.13uM) is low (lower than the 
concentration that induces cell death in cultured pituitary cells) and this may indicate 
that the barrier cells are protected from free iron-related ROS damage and cell death 
that may compromise BBB/BCB integrity. Even for extreme system iron loads the 
BBB/BCB cells are not exposed to toxic levels of free iron. 
As shown in figure 4.5C, the concentration of Tf-Fe in the ISF suddenly increases 
during the first day and reaches a maximum concentration, which is equal to the 
amount input to the serum. After several days, the concentration of Tf-Fe in the ISF 
drops to the steady state concentration (~23 µM). This result shows that, in a shift to 
high system-iron concentrations, iron may transiently increase in the ISF/CSF, but iron 
is rapidly controlled and reduced within a couple of days. The model postulate that 
while brain cells may see temporary iron increases, the BBB/BCB functions as a buffer 
to minimise long-term exposure to iron resulting from system iron fluctuations. For 
Tf-Fe serum lower than 20 µM, the uptake flux and the steady state concentration of 
the LIP and TF-Fe ISF are lower than for the other concentrations simulated. This may 
mean that, although excessive serum iron may not have much impact on the uptake 
and Tf-Fe ISF concentration, in the long run, the model predicts that serum iron 
deficiency may have a huge impact on brain iron concentration. 
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Figure 4.5 Metabolites in the model responding to various levels of increased iron load. (A) The 
rate of the iron uptake into the brain ISF. (B) The concentration of labile iron pool (LIP) in the BBB 
and BCB. (C) The concentration of Tf-Fe in the ISF. 
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4.3.3! Sensitivity analysis 
Generic sensitivity analysis and metabolic control analysis (MCA) were performed to 
investigate which reactions in the model have the highest control over the 
concentration of iron in the BBB, BCB and ISF. The generic sensitivity analysis 
describes how sensitive the model is to the parameter value and the MCA relays how 
much the rates of the various reactions in the model affect the fluxes and 
concentrations at steady state. There are two methods of calculating MCA available in 
COPASI; the Reder algorithm and the Smallbone algorithm. Both algorithms were 
performed and the results are compared below. The result from MCA simulation, 
concentration control coefficient, could be interpreted as the percentage change of the 
metabolite given a one percent change in the reaction rate. 
According to the literature, the smallbone method has overcome the limitation of the 
reder algorithm, however the MCA simulation using smallbone algorithm shows that 
the one percent changes in the IRP expression and degradation does not affect any 
metabolites, concentration control coefficient is 0. IRP is the main regulatory proteins 
in the system, so a one percent change in the expression and degradation of the protein 
was expected to affect the concentration of iron in the LIP in the BBB and the BCB, 
and in the ISF. The generic sensitivity analysis and MCA results for the concentration 
of the LIP in the BBB, the LIP in the BCB and the Tf-Fe in the ISF are listed in order 
of highest magnitude in tables 4-4, 4-5 and 4-6, respectively. 
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Table 4-4 Generic sensitivity analysis (sensitivity coefficient (SC)) and metabolic control analysis 
(concentration control coefficient (CCC)) for LIP in BBB 
sensitivity reder smallbone 
reaction 
parameter SC reaction CCC reaction CCC 
k1 of binding of 
Tf-Fe to TfR 
BBB 
0.766 TfR_BBB 
expression 0.767 
Fpn_BBB 
export -1.000 
k1 of 
degradation of 
TfR BBB 
-0.766 TfR_BBB –Tf-
Fe binding 
0.767 
TfR_BBB-2Tf-
Fe binding 0.841 
a of export by 
Fpn BBB 
-0.766 TfR_BBB 
degradation -0.767 
Fpn_BBB 
degradation 0.302 
K of 
degradation of 
FPN BBB 
-0.568 Fpn_BBB 
export 
-0.767 
Fpn_BBB 
expression -0.302 
k1 of 
degradation of 
IRP BBB 
-0.409 IRP_BBB 
expression 
0.409 
TfR_BBB –Tf-
Fe binding 0.122 
K  of expression  
of TfR BBB 
-0.369 IRP_BBB 
degradation -0.409 
TfR_BBB iron 
internalisation 0.037 
a of degradation 
of FPN BBB 
0.227 Fpn_BBB 
degradation 0.227   
K of export by 
Fpn BBB 
0.227 Fpn_BBB 
expression -0.227   
a of expression  
of FPN BBB 
-0.227     
n of export by 
Fpn BBB 
-0.196     
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Table 4-5 Generic sensitivity analysis (sensitivity coefficient (SC)) and metabolic control analysis 
(concentration control coefficient (CCC)) for LIP in BCB 
sensitivity reder smallbone 
reaction 
parameter SC reaction CCC reaction CCC 
a of export by 
Fpn BCB 0.970 
Fpn_BCB 
export -0.974 
Fpn_BCB 
export -1.000 
k1 of binding of 
Tf-Fe to TfR 
BBB 
0.766 TfR_BBB degradation -0.861 
TfR_BBB-2Tf-
Fe binding  0.841 
k1 of degradation 
of TfR BBB 0.766 
TfR_BBB 
expression 0.861 
Fpn_BCB 
degradation 0.296 
K of degradation 
of FPN BCB 0.720 
TfR_BBB-
Tf-Fe 
binding  
0.861 Fpn_BCB expression -0.296 
K of expression  
of TfR BBB 0.369 
IRP_BBB 
expression 0.319 
TfR_BBB-Tf-
Fe binding  0.122 
k1 of degradation 
of IRP BBB 0.358 
IRP_BBB 
degradation -0.319 
TfR_BBB iron 
internalisation 0.037 
a of degradation 
of FPN BCB 
0.288 Fpn_BCB 
degradation 
0.307   
K of export by 
Fpn BCB 0.288 
Fpn_BCB 
expression -0.307   
a of expression  
of FPN BCB 0.288     
n of export by 
Fpn BCB 0.248     
K of expression  
of IRP BBB 0.204     
a of export by 
Fpn BBB 
0.204     
K of degradation 
of FPN BBB 0.152     
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Table 4-6 Generic sensitivity analysis (sensitivity coefficient (SC)) and metabolic control analysis 
(concentration control coefficient (CCC)) for Tf-Fe in ISF 
local sensitivity reder smallbone 
reaction parameter SC reaction CCC reaction CCC 
k2 of flow of Tf-Fe 
between ISF and 
CSF 
1.000 TfR_BBB expression 1.000 
TfR_BBB-2Tf-
Fe binding  0.873 
k1 of binding of Tf-
Fe to TfR BBB 
1.000 TfR_BBB-Tf-
Fe binding  1.000 
TfR_BCB-2Tf-
Fe binding  -0.873 
k1 of degradation of 
TfR BCB 
1.000 TfR_BBB 
degradation 
-1.000 TfR_BBB-Tf-
Fe binding  
0.127 
k1 of flow of Tf-Fe 
between ISF and 
CSF 
-
0.999 
TfR_BCB 
expression -1.000 
TfR_BCB-Tf-
Fe binding  -0.127 
k1 of degradation of 
TfR BBB 
-
0.999 
TfR_BCB 
degradation 1.000 
TfR_BBB iron 
internalisation 0.039 
k1 of binding of Tf-
Fe to TfR BCB 
-
0.999 
TfR_BCB-Tf-
Fe binding -1.000 
TfR_BCB iron 
internalisation -0.039 
K of expression  of 
TfR BCB 
0.481 IRP_BBB 
degradation 
-0.467   
K of expression  of 
TfR BBB 
-
0.481 
IRP_BBB 
expression 0.467   
k1 of degradation of 
IRP BCB 0.467 
IRP_BCB 
expression -0.467  !
k1 of degradation of 
IRP BBB 
-
0.467 
IRP_BCB 
degradation 0.467  !
a of export by Fpn 
BBB 
0.266 Fpn_BBB 
export 0.267  !
K of expression  of 
IRP BBB 
0.266 Fpn_BCB 
export 
-0.267  !
a of export by Fpn 
BCB 
-
0.266    !
K of expression  of 
IRP BCB 
-
0.266    !
K of degradation of 
FPN BBB 0.198    !
K of degradation of 
FPN BCB 
-
0.198    !
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The control over the labile iron pools in the two barriers, the BBB and the BCB, were 
of interest because these iron pools are more prone to involvement in the generation 
of ROS by Fenton chemistry (table 4-4 and 4-5)[133]. According to the sensitivity 
coefficient, the reaction parameters that have highest control over the LIP in the BBB 
are the ‘Km’ parameter for TfR in the BBB binding to the first Tf-Fe, the ‘K’ parameter 
of the degradation of the TfR BBB and a parameter of iron export out of the BBB by 
ferroportin. The ‘k’ parameter for the degradation of ferroportin and the IRP in the 
BBB also has some degree of control over the concentration of the LIP in the BBB. 
The concentration control coefficient with the Reder MCA similarly shows that the 
binding of TfR in the BBB to the first Tf-Fe, the expression and degradation of TfR 
BBB and the exportation of iron out of the BBB have the highest control over the 
concentration of the LIP in the BBB. The expression and degradation of IRP and 
ferroportin in the BBB also have an effect on the concentration of LIP in the BBB, 
though to a lesser extent. The concentration control coefficient result with the 
Smallbone MCA algorithm indicated that the iron export reaction by ferroportin has 
the highest control over the LIP concentration in the BBB. The Smallbone result also 
shows that the reaction of the binding of the Tf-Fe to TfR in the BBB and the 
internalisation of the TfR Tf-Fe complex also have some degree of effect on the 
concentration of the LIP in the BBB. This result is different from the Reder algorithm 
results and generic sensitivity results which indicated that small changes in these two 
reactions are not significant. 
The sensitivity analysis for the concentration of the LIP in the BCB shows that the ‘a’ 
parameter of iron export out of the BCB by ferroportin has the most significant control 
over the concentration. This was followed by the ‘k’ parameter of the binding of the 
first Tf-Fe onto TfR in the BBB, the ‘k’ parameter of the degradation of BBB TfR, 
and the ‘k’ parameter of the degradation of BCB ferroportin. The MCA result using 
the Reder algorithm showed a similar result with the iron export out of the BCB by 
ferroportin as the reaction most affecting the concentration of the LIP in the BCB. The 
expression and degradation of the BBB TfR and the binding of the first Tf-Fe to BBB 
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TfR also affects the concentration of LIP in the BCB according to Reder. The 
expression and degradation of the ferroportin protein have a lesser effect, although 
they are still significant. Like the two methods, the results with the Smallbone 
algorithm also demonstrate that the exportation of iron by ferroportin out of the BCB 
has the greatest effect on the concentration of LIP in the BCB. Unlike the other two 
methods, the next significant reactions that have control over BCB LIP according to 
the Smallbone algorithm are the binding of the second Tf-Fe on the TfR in the BBB 
and the internalisation of iron by TfR in the BBB.  
The control over the concentration of Tf-Fe in the ISF is listed in table 4-6. The generic 
sensitivity coefficient implies the parameters for the two way flow between the ISF 
and CSF, the parameters for TfR degradation reaction in both the BBB and BCB, and 
the parameters for the binding of first iron to TfR in both the BBB and BCB have the 
highest control over the concentration of Tf-Fe in the ISF. Others reaction parameters 
that show some level of control are the expression of TfR in the BBB and BCB and 
the degradation of IRP in the BBB and BCB. The results from the Reder method show 
that the reactions involving TfR have the most significant effect on the concentration 
of Tf-Fe in the ISF. These reactions are: the expression and degradation of TfR in the 
BBB and BCB; and the binding of the first Tf-Fe onto the TfR in the BBB and BCB. 
The results of the Smallbone algorithm indicate that it is the binding reaction of the 
second Tf-Fe to TfR in the BBB and the BCB that have higher control over the 
concentration of ISF Tf-Fe rather than the binding of the first Tf-Fe onto the TfR in 
the BBB and BCB. The concentration of Tf-Fe in the brain ISF is controlled by the 
binding of Tf-Fe to TfR in the BBB and BCB and the internalisation of Tf-Fe in both 
barriers. A slight change in the rates of reaction for other proteins in the system appears 
to have less control over the concentration of Tf-Fe transported into the brain ISF. 
4.3.4! Metabolite expression rates 
The concentration control coefficient of the MCA results in the previous section 
predicts that TfR plays an important role in the transport of Tf-Fe into the brain. 
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Therefore in this section, the effect of changing the expression rate of either TfR or 
IRP in the BBB and BCB under different iron conditions is presented. The different 
conditions are: healthy serum iron condition (20 µM [14, 132]); serum iron deficiency 
condition (2 µM [132]); and serum iron overload condition (200 µM). Figure 4.6 
shows the concentration of Tf-Fe in the ISF and the LIP in the BBB and BCB when 
the expression rate of either TfR or IRP is 0.5x, 1x, 2x and 4x in both barriers 
simultaneously under the three conditions. Figure 4.6 shows that under normal iron 
conditions, the concentration of Tf-Fe in ISF decreases when the rate of TfR or IRP 
expression in both barriers is higher than the normal rate (1x).The concentration of the 
LIP in the BBB and BCB, increase with higher rate of TfR or IRP expression rate.  
Under iron deficiency condition, the steady state concentration of Tf-Fe in the brain 
ISF is unchanged but the concentration of LIP in both the BBB and BCB increases 
linearly with increasing expression rate of TfR and IRP. Under iron overload 
condition, the LIP in the BBB and BCB are unaffected by the TfR expression rate, 
while an increase in the rate of IRP expression slightly increases the concentrations. 
The concentration of Tf-Fe in the ISF, in contrast, decreases as the rate of TfR or IRP 
expression rate increases in both the BBB and the BCB. 
Figures 4.7 and 4.8 show the effect of an imbalance in the expression of TfR and IRP 
between the BBB and BCB under the three different conditions. Figure 4.7 shows the 
concentration of Tf-Fe and LIP in the BBB and the BCB when the expression rate of 
TfR or IRP in the BBB is either increases or decreases, while the expression rate of 
TfR or IRP in the BCB is kept constant. The responses under the normal and iron 
deficiency conditions are again similar. Under these two conditions, higher expression 
rate of TfR/ IRP in the BBB increases the concentration of Tf-Fe in the ISF and the 
LIP in the BBB and BCB. Under iron overload condition, the concentration of Tf-Fe 
in the ISF and the LIP in the BBB and BCB stay constant as the expression rate of TfR 
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Figure 4.6 The effect of system-wide expression changes in TfR and IRP on the concentration of 
Tf-Fe in ISF and labile iron pool in both BBB and BCB under 3 conditions: normal iron serum 20 
µM, iron deficiency 0.2 µM and iron overload 200 µM. This shows that system-wide changes in 
the expression rate of TfR and IRP decrease the concentration of iron in the brain ISF under normal 
and overload condition, but do not significantly change the amount of iron reaching the ISF under 
iron deficiency condition. There appears to be a shift on the effect of TfR or IRP expression with 
insufficient iron in the serum. 
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Figure 4.7 The consequences of perturbations of IRP and TfR expression only in BBB under 3 
conditions: normal iron serum 20 µM, iron deficiency 0.2 µM and iron overload 200 µM. This 
shows that changes in BBB expression rate of TfR and IRP do not affect the concentration of iron 
in the brain ISF, as well as LIP in BBB and BCB, under normal and overload condition, but 
significantly change the amount of iron reaching the ISF and LIP under iron deficiency condition. 
There appears to be a shift on the effect of TfR or IRP expression with insufficient iron in the serum. 
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Figure 4.8 The consequences of perturbations of IRP and TfR expression only in BCB under 3 
conditions: normal iron serum 20 µM, iron deficiency 0.2 µM and iron overload 200 µM. This 
shows that under all three conditions the changes in BBB expression rate of TfR and IRP decrease 
the concentration of iron in the brain ISF, but has no/ slight effect on the LIP in BBB and BCB. 
 
 
89 
 
or IRP in the BBB changes, except for the slight increases in the LIP in the BBB 
concentration when the IRP expression in the BBB increases. 
Figure 4.8 shows the response of Tf-Fe in the ISF and the LIP in the BBB and BCB 
when the expression of TfR in the BCB is varied while in the BBB the TfR expression 
rate is kept at its normal level. Unlike the previous two simulations, the results 
determined by varying the expression of TfR or the IRP rate in the BCB appear to be 
similar across the three conditions. The concentration of Tf-Fe in the ISF decreases 
with an increasing expression rate for TfR or IRP in the BCB, while the steady state 
concentration of the LIP in the BBB stays constant. The concentration of LIP in BCB 
is affected by the increasing expression rate of IRP in the BCB, but not by the 
increasing rate of TfR in the BCB. 
4.3.5! Iron uptake in response to varying iron usage in the brain 
As previously mentioned, iron is involved in numerous metabolic reactions in the 
brain cells. A condition was simulated where the usage of iron in the brain ISF is 
(temporarily) increased to examine the resulting iron uptake across the barriers, 
especially the BBB. The result of the simulation (figure 4.9) shows that a spiked 
increase in the use of Tf-Fe in the ISF over a one day period affects the concentration 
of the ISF Tf-Fe, but does not perturb the concentration of LIP in BBB. Figure 4.9A 
shows that the rate of the temporary use of the Tf-Fe in the ISF was set to spike at 0.2 
µM/s after a period of half a day before returning to the initial rate. The simulation 
result shows that the concentration of Tf-Fe in the ISF decreases as the rate of Tf-Fe 
usage increases, as shown in figure 4.9C. The concentration of Tf-Fe in the ISF reaches 
0.364 µM when the usage rate reaches its peak.  In comparison, the concentration of 
the LIP in the BBB (figure 4.9B) stays at the steady state value throughout the 
increased Tf-Fe usage in the ISF. This result shows that the BBB in this model does 
not compensate for the loss of Tf-Fe concentration in the ISF, which may not be the 
ideal response to a reduced brain iron concentration. The simulation over a longer 
period of time, over a year, of high iron consumption in the ISF shows the same result 
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as the simulation over a day range, the concentration of the Tf-Fe is low during high 
iron usage in the ISF and the concentration of the LIP in the BBB stay constant, as 
shown in figure 4.9D – F. The LIP and ferritin (not shown) in the BBB in the model 
do not compensate for the loss of iron in the ISF. The concentration of the metabolites 
and the rates of the reactions in the BBB are unaffected by the increase in usage of Tf-
Fe in the ISF.   
 
Figure 4.9 Iron uptake across the BBB in response to a temporary increase in the rate of Tf-Fe ISF 
usage. (A) The signal triggered to simulate an increase in Tf-FE ISF usage for one day period. The 
set peak rate of Tf-Fe usage in the ISF is 0.20 µM s-1. (B) The concentration of the LIP in the BBB 
and (C) Tf-Fe in ISF in response to an increase in the ISF Tf-Fe consumption signal in A. (D) The 
signal triggered to simulate an increase in Tf-FE ISF usage for a long period of time (more than 200 
days). (E) The concentration of the LIP in the BBB and (C) Tf-Fe in the ISF in response to an 
increase in the ISF Tf-Fe consumption signal in D. 
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! Discussion 
Iron is one of the essential metals in the brain and is involved in many metabolic 
reactions. The exact course of iron transport into the brain is still not fully understood; 
therefore, we have created a mathematical model of iron transport across the brain 
barrier systems. This new model provides an in silico resource to explore the brain 
iron transport system and the impact of brain iron dysregulation. The currently 
available iron uptake model in the brain by Simpson et al. (2014) [134] also recognised 
the BBB role in controlling the uptake of iron into the brain. However, they do not 
capture the system in complete detail because they have excluded the IRP, which 
regulates the expressions of the transport proteins (TfR, DMT1, ferroportin) and 
ferritin, from their model. 
They have also hypothesised that TfRs are expressed on the abluminal side of the 
BBB, and it is TfRs that are responsible for sensing the iron saturation level [134]. 
This suggestion is still not yet backed up by sufficient experimental evidence, and 
there is also not enough evidence to prove the presence of abluminal TfR in the BBB. 
Therefore, this was not incorporated this into our model. 
The brain barrier systems model simulations accurately replicate, in a qualitative 
sense, the form of the curves of the iron uptake kinetics across the BBB. This is 
evidenced in the quality of fit (chi squared value is approximately 0.04), obtained by 
fitting the simulated curves with independently-determined data from various 
experimental systems. The agreement is qualitative, not quantitative, because the 
absolute values are different even though there is good agreement in the form of the 
curves. In response to increasing Tf-Fe concentration in the serum, the concentration 
of Tf-Fe bound to TfR increases and saturates. The simulated kinetics appear to be 
comparable to experimental results obtained by Hill et al. (1985) [130]. The simulation 
and experimental TfRs reach maximum occupancy at a low concentration. It is 
suggested that serum iron levels towards iron overload would not cause a significant 
increase in the iron uptake rate into the BBB. We also studied the dynamics of brain 
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iron uptake in response to a serum Tf-Fe injection. The model shows similar dynamics 
to the time course study from rat brains by Taylor and Morgan (1990) [131]. The 
parameter values used in this model were derived from data from in vitro experiments 
and animal studies. The use of these parameters may raise doubts as to the validity of 
the model as often in vitro experiments do not perfectly mimic in vivo conditions and 
animal models are not equivalent to human models. Despite this limitation, the model 
is able to qualitatively replicate experimental observations that were not applied in the 
model calibration process (shown in figure 4.3 and 4.4).  
The concentration of iron in the brain is more stable than in the liver. As the only 
barrier separating the two, it has been postulated in the literature that the BBB is 
mainly responsible for regulating the homeostasis of iron in the brain [7, 32, 134]. We 
simulated time courses of the model in response to an increasing constant 
concentration of Tf-Fe in the serum (figure 4.5). The model shows that increasing the 
concentration of serum Tf-Fe does not increase the rate of iron uptake into the brain. 
The barriers appear to limit the rate of uptake of iron into the ISF. As a result of the 
controlled iron uptake rates and intracellular iron buffering, the concentration of LIP 
in the barriers remains below 0.15 µM even when challenged by high serum Tf-Fe 
level. Thus the model shows that the integrity of the barriers would be protected in an 
iron overload case. The concentration of iron in the ISF is also predicted to saturate at 
~23 µM, which is relatively low compared to the iron concentration inside the brain 
tissue. In the earlier part of the time course (figure 4.5C), the concentration of ISF iron 
increases sharply to a concentration similar to the input serum Tf-Fe before it declines 
to a steady state concentration after five days. This result supports the postulation that 
the BBB can regulate the homeostasis of iron in the brain. The model shows that the 
concentration of iron in the ISF is also quickly regulated to a safe level, even when the 
concentration of iron added into the model is six times the normal concentration (~20 
µM) [14]. The regulation of iron is important with respect to the overall concentration 
of iron in the brain as the brain cells, neurones and glia are directly exposed to it. By 
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controlling the ISF and CSF iron level, the model shows that the BBB and BCB have 
a regulating capacity that agrees with previous hypotheses. 
Sensitivity analyses were performed to evaluate how much changes in a specific 
parameter affect the metabolites in the model. Generic sensitivity measurements 
produced sensitivity coefficients in response to a small change in the specific 
parameters of a reaction. The MCA produced concentration control coefficients that 
describe how much a small change in the rate of a specific reaction affects the 
concentration of the metabolite of interest. Two different algorithms in COPASI were 
employed to perform the MCA: the Reder and Smallbone algorithm. The Reder 
algorithm is only valid under certain circumstances and the Smallbone algorithm is 
supposed to remove this limitation. However, our results show that using the 
Smallbone algorithm, the concentration control coefficient for all of the metabolites 
in respect to small changes in IRP expression and degradation in both the BBB and 
the BCB are zero. This is not the case with the Reder algorithm as well as generic 
sensitivity analysis which indicate that IRP expression and degradation have 
significant control over the concentration of the LIP in the BBB and the BCB and Tf-
Fe in the ISF. Based on this result, we will rely more on the result from the Reder 
algorithm for the MCA to determine the reactions that affect the metabolites of 
interest. 
The results from the sensitivity analysis show that the protein that has the most control 
over the concentration of the LIP in the BBB and the Tf-Fe in the ISF is TfR, followed 
by ferroportin and IRP. For the concentration of the LIP in the BCB, the protein that 
has most control is the ferroportin followed by TfR and IRP. The reactions involving 
the transport protein TfRs on the surface of both the BBB and the BCB have the 
highest control over iron transported into the brain. The IRPs in the BBB and the BCB 
also a significant effect on the concentration of the Tf-FE in the ISF. Because the 
expression of the IRP is regulated by the concentration of the LIP in the BBB and the 
BCB, this may indicate that intracellular iron status in BBB/BCB epithelial cells could 
modulate iron concentrations available to cerebral tissue. 
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To investigate the effect of the abundance of the TfR and IRP, the concentration of the 
LIP in the BBB and the BCB and Tf-Fe in the ISF in response to different expression 
rates of the proteins. The results of the simulations are shown in figures 4.6, 4.7 and 
4.8.  Figure 4.6 shows that under normal and iron overload condition, when the 
expression rates of TfR in the BBB and BCB are varied simultaneously, the system-
wide change of TfR on the barriers does have an impact on the amount of iron inside 
the BBB and the BCB and transported into the ISF. In this condition, higher than 
normal expression rate of TfR or IRP means reduced concentration of iron transported 
into the ISF, but higher LIP in both the BBB and the BCB. The result for iron 
deficiency condition shows that the system-wide change of TfR affects the iron in the 
BBB and BCB, but not the iron in the brain ISF. While in iron overload conditions, 
the system-wide change of TfR affects the iron in the brain ISF, but not the iron in the 
BBB and BCB. There appears to be a different regulation system for the iron uptake 
across the BBB and BCB in these three different conditions. This shift in regulation 
indicates the importance of experimental context when attempting to control iron 
metabolism with drugs and the potential for drug targets specific to iron deficiency 
that would avoid side effects when iron levels return to normal.  
Simulations varying TfR or IRP expression rates in either the BBB independently (i.e. 
not in both the BBB and the BCB simultaneously) were performed and are shown in 
figure 4.7. In normal and overload conditions, the increase in TfR or IRP expression 
seems not to alter the concentration of iron transported into the brain and the barriers, 
whilst in iron deficiency, the concentration of Tf-Fe increases with increasing TfR in 
the BBB. From these results, it seems that, depending on whether there is sufficient 
concentration of the iron in the serum or not, the concentration of TfR may or may not 
have a notable effect on the transport of iron into the brain. 
In all the conditions examined, the concentrations of LIP in the BBB and the BCB stay 
at ~0.15µM, which is below 1.2µM, the concentration of iron that kills anterior 
pituitary cells [135]. The higher concentration of the LIP in the barrier increases the 
possibility of redox reaction occurring which may lead to cell death and loss of the 
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barrier integrity. According to the simulation, an increased expression rate of TfR or 
IRP in both barriers and only in the BBB or the BCB does not increase the probability 
of the BBB and the BCB losing their integrity due to a redox reaction.   
Figure 4.5 shows how the model effectively responds to iron overload conditions in 
the serum. To investigate further how the BBB preserves iron homeostasis in the brain, 
a situation where there is a loss of iron in the brain ISF due to an increase in the uptake 
of iron into the nearby brain cells was simulated (figure 4.9). The result of this 
simulation shows that the BBB in the model does not maintain a steady state 
concentration of iron in the local ISF. The simulated high consumption reaction of the 
ISF Tf-Fe keeps the concentration of the Tf-Fe in the ISF relatively low over that 
period of time, while the concentration of all of the metabolites in the BBB stays at a 
steady state and the rate of the reactions in the BBB stay constant. The BBB model 
does not appear to balance the loss of the Tf-Fe in the nearby ISF. The probable 
reasons for this simulation result are: (1) the lack of feedback from the ISF 
compartment to the BBB and (2) the BBB stops providing more iron into the iron 
packed local cells. 
One of the conclusions that can be taken from the simulation result shown in figure 
4.9 is the suggestion that the presence of a positive feedback mechanism is required to 
ensure sufficient iron entering the brain. This function may be performed by hepcidin 
or a metabolite playing a role equivalent to hepcidin; there is very little evidence as 
yet for the presence of hepcidin in the BBB and this remains unconfirmed and a subject 
of debate. Hepcidin is mostly expressed in the liver and in this model, the 
concentration of hepcidin in both barriers is kept constant because of the theory that 
hepcidin protein found in the brain originates in the liver [73]. There are data showing 
that the hepcidin protein is widely distributed in the brain, however, its expression and 
presence in and in the vicinity of the BBB is not yet well established [73]. In recent 
years, there are research findings in human tissue and cells that show the presence of 
hepcidin mRNA and its expression in the astrocytes, cells that surround the brain 
capillaries, ex vivo and in cell culture [136, 137]. Another study found that an increase 
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in the concentration of iron in the astrocytes decreases the uptake of iron by the BBB, 
which further supports the feedback mechanism theory [134]. TfR2 and HFE protein 
that modulate the hepcidin levels in the liver are found in the brain [137], but have not 
yet been found in the abluminal side of the BBB. The mechanism by which the 
hepcidin acts as a regulator of iron export in the BBB is still under study. 
In this chapter, an in silico model that represents the brain barrier systems in the human 
brain was developed and tested under different iron conditions and different 
expressions of important metabolites. The brain barrier systems model protected the 
brain from brain iron overload, which is consistent with the main predicted function 
of BBB and BCB in the human brain [21]. The model provides an in silico resource 
to begin exploring and predicting the impact of iron dysregulation in 
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. 
Investigations that can only be undertaken by computational systems modelling, such 
as metabolic control analysis, provide new insights into the most critical function in 
the regulation of iron metabolism in health and disease. Important iron pathways in 
the disease may thereby be identified using this model, and these pathways could then 
be targeted in the model with simulated drug action. In the future, by adding a species 
to represent an iron modifying drug, as the therapeutic agent, the model could be 
integrated with a pharmacokinetic/pharmacodynamic model. This upgraded version 
of the model would be useful to improve understanding of the mechanism of action of 
existing therapeutics and to predict effective targets for novel therapeutics. Moreover, 
this model with the simulated drug action is a current priority as clinical trials of iron 
modifying drugs as protective agents are currently underway for PD and AD [20]. 
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In chapter 4, a computational model that describes the brain iron uptake was presented. 
The model described the tightly regulated iron uptake into the brain interstitial fluid 
(ISF), which was treated as the ‘brain’. This model does not include the transport of 
iron into the dopaminergic neurone (DA) neurone, which, as previously mentioned, is 
the cell that is highly involved in the progression of the Parkinson’s disease (PD). The 
disruption of brain iron homeostasis in PD is distinguished by an increase in iron 
concentration and increased cell death in certain areas in the brain, the DA neurone 
cells in the substantia nigra (SNpc) being the area that is most obviously affected in 
these respects. In order to explore the role of iron in the DA neurone, a completely 
original computational model that describes brain iron homeostasis in the DA 
neurones in health, and under conditions of iron overload, was developed for future 
application to PD using the same principles as the model in chapter 4. This new model 
is the subject of Chapter 5. 
The main characteristic that differentiates the DA neurone in the SNpc from other 
types of neurone is the dark brown pigment called neuromelanin [138]. Neuromelanin 
binds to metal, primarily iron in the neurone. Neuromelanin has two different iron 
binding sites, high affinity binding sites with a disassociation constant KD of ~ 10 nM 
and low affinity binding sites with a disassociation constant KD of ~ 100 nM [139]. 
Iron bound to the neuromelanin high affinity binding sites is internalised into the 
neuromelanin core in a similar fashion to ferritin. By using Mossbauer spectroscopy, 
Chapter 5! Modelling iron metabolism in 
dopaminergic neurone of the Substantia nigra 
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Gerlach et al. (1995) showed that these binding sites appear to be similar to those in 
ferritin [140]. Iron sequestered by neuromelanin is redox inactive, but the iron bound 
to the low-affinity binding sites in neuromelanin has been linked to the formation of 
redox active complexes [15, 141]. The mechanism of iron binding to neuromelanin 
and its release is still under investigation [142]. The binding of iron to neuromelanin 
is included in the model presented in this chapter, to investigate the interaction of iron 
with neuromelanin in the health and PD. 
Similar to iron uptake in the BBB and the BCB in chapter 4, in the DA neurone, two 
transferrin proteins bind to iron (Tf-Fe) in the ISF then bind to TfRs on the surface of 
the DA neurones. The binding initiates receptor-induced endocytosis of the 2 Tf-Fes. 
Inside the endosome, iron is chemically reduced and released into the labile iron pool 
(LIP) in the cytosol of the DA neurone, and TfR-Tf is recycled back to the surface of 
the neurone. Iron in the LIP may be involved in the production of dopamine and other 
processes [36]. Any excess iron is stored in neuromelanin or ferritin, or transported 
back out of the neurone by the ferroportin into the ISF. The expression of TfR, 
ferroportin, DMT1 and ferritin is monitored and governed by IRP [143]. 
 
Figure 5.1 Illustration of the flow of iron between the blood and the brain including the DA 
neurone. The fenestrated cells between the ISF and the CSF allow free exchange of iron, but the 
direction of the fluid bulk flow is principally from the ISF into the CSF. The arrows represent the 
direction of the iron transport and the dotted arrow represents the weaker flow of Tf-Fe from ISF 
to CSF. 
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In this chapter, a new compartment, representing the DA neurone, is added to the prior 
model presented in chapter 4 as shown in the illustration of the flow of iron in figure 
5.1. The updated model describes a mechanistic computational model of iron transport 
 
Figure 5.2 Conceptual biological diagram for iron uptake in the brain from which the model in this 
chapter derived. The direction of the flow of iron is shown in figure 5.1. Abbreviations: BBB: blood 
brain barrier, BCB: blood cerebrospinal fluid, BCEC: brain capillary endothelial cell (comprises 
the BBB), CPEC: choroid plexus epithelial cell (comprises the BCB), CSF: cerebrospinal fluid, DA 
neurone: dopaminergic neurone, DMT1: divalent metal transporter 1, Fe: iron, Fpn: ferroportin, Ft: 
ferritin, Hepc: hepcidin, IRP: iron response protein, ISF: interstitial fluid, LIP: labile iron pool, Tf: 
transferrin, Tf-Fe: transferrin bound iron, TfR: transferrin receptor. 
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and regulation between the serum and the dopaminergic neurones. Using this 
computational model, the uptake of iron into the DA neurone will be explored. 
! Materials and methods 
As in chapter 4, the multi-compartment in silico model of brain iron trafficking into 
the DA neurone has been created using COPASI. The model comprises nonlinear 
ordinary differential equations to characterise the kinetics of each chemical species 
incorporated. The methodology for modelling the combined iron metabolism in the 
BBB and BCB and the dopaminergic neurones was performed following the 
approaches described in chapter 4 section 4.2, unless stated below. A new 
compartment, describing the dopaminergic neurones, was added into the brain barrier 
system’s iron metabolism. The schematics assumed the uptake of iron into the brain 
and the DA neurone included in the new model are shown in figure 5. 2. The process 
diagram for the model is depicted in System Biology Graphical Notations (SBGN) in 
figure 5. 3. The model consists of six compartments: blood serum, the BBB, the ISF, 
the CSF, the BCB, and the DA neurone in the SNpc. The volume of the DA neurone 
in this model is 5.5 x103 l. This number was acquired by multiplying the volume of 
pigmented neurones, 17983 µm3, with the number of pigmented neurones, 3.045 x 108 
[144]. The volume of the remaining compartments were kept unchanged. Also, all 
existing reactions incorporated in the original model and associated parameters were 
preserved. 
In the DA neurone of the SNpc, the density of the TfR binding sites was estimated 
experimentally to be less than 4 x 10-12 mol/g tissue [87, 145]. By using the assumption 
that the density of brain cells is the same as water (~1000 g/l), the estimated 
concentration of TfR protein in the DA neurone is; 4 x 10-12 × 1000 = 4 x 10-9 M, 4 x 
10-3 µM for TfR protein in the DA neurone. This value is ~100x lower than the value 
of TfR concentration in the liver (0.46 µM) [124, 145]. The parameter for the 
expression rate of TfR in the DA neurone was set to be 100x lower than that in the 
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Figure 5.3 System Biology Graphical Notation (SBGN) process diagram of iron trafficking in the 
human brain barrier system and dopaminergic neurone model based on the mechanistic 
representation of the biological system shown in figure 5.2. Complexes are represented in boxes 
with component species. In the special case of the ferritin-iron complex, the amount for each 
species are not depicted in stoichiometric quantities (there are thousands or iron ions per ferritin). 
Species overlaid on the compartment boundaries represent membrane-associated species. 
Abbreviation: AS: ascorbate, BBB: blood brain barrier, BCB: blood cerebrospinal fluid, CSF: 
cerebrospinal fluid, DA neurone: dopaminergic neurone, DMT1: divalent metal transporter 1, Fe: 
iron, Fpn: ferroportin, Ft: ferritin, IRP: iron response protein, LIP: labile iron pool, NM: 
neuromelanin, Tf-Fe Serum: transferrin bound iron in the blood plasma, TfR: transferrin receptor. 
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 liver, from 6 x 10-12 s-1 to 6 x 10-14 s-1 [94]. All other reactions involved in the iron 
endocytosis in the DA neurone were assumed to be identical those in the BBB and 
BCB. The reactions and parameters used are listed in table 5-1.  
The concentration of the neuromelanin was derived by taking the average of the 
neuromelanin concentration shown in the figure in the paper by Zecca et al. (2001) 
[146]. The concentration of the neuromelanin was derived by multiplying the amount 
of available binding sites (6 x 1020 sites per g) [147] by the amount of neuromelanin 
available in the SNpc (2 x 10-3 g neuromelanin/ g wet tissue); 6 x 1020 × 2 x 10-3 = 1.2 
x 1018 sites/ g wet tissue. Assuming that the density of brain cells is the same as water 
(~1000 g/l); 1.2 x 1018× 1000 = 1.2 x 1021 sites/ l wet tissue. Using the Avogadro’s 
constant, the molar concentration is calculated; 1.2 x 1015/6.023 x 1023= 2 x 10-3 M, 2 
x 103 µM of neuromelanin. Neuromelanin incorporates two different binding sites for 
iron; high (KD = 7.18 ±1.08 nM) and low (KD =94.31 ± 6.55 nM) affinity sites [139]. 
Neuromelanin binds to iron in the ferric form iron core similar to ferritin, thus 
neuromelanin was modelled in the same way as ferritin, using equations Eq. 4.14 and 
Eq. 4.15. The on and off binding rates for both the high and low affinity binding sites 
were adjusted with minimal changes from the ferritin kinetics, using the following 
equation: 
!"#$ =
!#$&''
!#$&(
=
!')**+,+(&'' -
- ∗ /!')**+,+(&(
/ 
Unlike ferritin, neuromelanin does not appear to oxidise ferrous iron into ferric iron 
[148], so iron oxidation and reduction reaction are added. The LIP in the DA neurone 
is oxidised by H202 producing ferric iron and hydroxyl radical. The hydroxyl radical 
then is degraded. It has a half-life of 10-9 s [149], which was used to calculate the 
degradation rate using Eq. 4.1. 
When simulating the neurodegenerative condition, some of the parameters in table 5-
1 were adjusted according to data found in the published literature as follows. The 
Eq. 5.1 
3.10 
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expression level of TfR was kept unchanged according to the result of post-mortem 
human brain studies comparing TfR level in healthy and PD subjects [87, 150]. The 
expression level of DMT1 and IRP in SN are increased by 11x and 3.5x, respectively, 
and the expression level of FPN in SN is decreased by 0.3x. These changes are 
according to the level of DMT1, IRP and ferroportin expression detected in Calcium-
independent phospholipase A2β (iPLA2β)-KO mice [151]. iPLA2β is encoded by the 
PLA2G6 gene. The mutation of this gene has been linked to PLA2G6-associated 
neurodegeneration (PLAN), which is the second most common type of 
neurodegeneration with brain accumulation (NBIA) [152]. In the experimental study, 
it has been shown that PLAN has some common iron accumulation pathways and 
degeneration in brain regions such as SN, so the result from this experiment in a mouse 
model was incorporated into the brain-iron-related simulation of a neurodegenerative 
condition [151]. In this thesis, this simulation will be called the PD/NBIA simulation.  
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Table 5-1 List of the reactions and their parameters for the DA neurone compartment in the extended model. 
Name Reaction Function  Parameters Ref 
TfR_DAN expression → TfR DAN; IRP DAN Hill function → a = 6 x 10-14 s-1 
n = 1 
K = 1x 10-6 mol 
[123, 
124] 
TfR_ DAN degradation TfR DAN → Mass action 
(irreversible) 
k = 8.37 x 10 -6 s-1 [124] 
TfR_ DAN binding 1 TfR_ DAN + Tf-Fe_ISF → TfR_ DAN -Tf-Fe_ISF Mass action 
(irreversible)  
k = 837400 
l*(mol*s)-1 
[42] 
TfR_ DAN release 1 TfR_ DAN -Tf-Fe_ISF → TfR_ DAN + Tf-Fe_ISF Mass action 
(irreversible) 
k = 9.142 x10-4 s-1 [42] 
TfR_ DAN binding 2 TfR_ DAN -Tf-Fe_ISF + Tf-Fe_ISF → 2(Tf-Fe)-TfR_ DAN Mass action 
(irreversible) 
k = 121400 
l*(mol*s)-1 
[42] 
TfR_ DAN release 2 2(Tf-Fe)-TfR_ DAN → TfR_ DAN -Tf-Fe_ISF + Tf-Fe_ISF Mass action 
(irreversible) 
k = 3.535 x10-3 s-1 [42] 
TfR_ DAN iron 
internalisation 
2(Tf-Fe)-TfR_ DAN ↔ 4 * endoFe3_ DAN + TfR_BBB Mass action 
(reversible) 
k1 = 0.8333 s-1, k2 = 
0.1 l5*(mol4*s)-1 
[42] 
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Name Reaction Function  Parameters Ref 
Steap3_ DAN iron 
reduction 
endoFe3_DAN → endoFe2_DAN Henri-Michealis-
Menten  
Km = 7.4 x10-5 
mol*l-1, V = 1.493 
x10-4 mol (l*s)-1 
[94] 
DMT1_ DAN 
expression 
→ DMT1_DAN;  IRP_DAN Hill function → a = 1.39 x10-10 s-1, n 
= 1, K = 2.5x10-6 mol 
[94] 
DMT1_ DAN 
degradation 
DMT1_DAN → Mass action 
(irreversible) 
k = 2.4x10-5 s-1 [94] 
DMT1_ DAN 
endosomal export 
endoFe2_DAN → LIP_DAN;  DMT1_DAN Henri-Michealis-
Menten  
kcat = 258.6 s-1, Km = 
4.8 x10-6 mol*l-1 
[94] 
IRP_ DAN expression → IRP_DAN;  LIP_DAN Hill Function -| a = 4x10-11 mol*(l*s)-
1, n = 1, K = 1x10-7 
mol 
[47] 
IRP_ DAN degradation IRP_DAN → Mass action 
(irreversible) 
k = 1.597 x 10-5 s-1 [126] 
Fpn_ DAN expression → Fpn_DAN;  IRP_DAN Hill function -| a = 1x10-9 mol*(l*s)-
1, n = 1, K = 1x10-7 
mol 
[94] 
Fpn_ DAN degradation Fpn_DAN →;  Hepcidin_DAN Biochemical hill 
function → 
a = 2.315x10-4 
mol*(l*s)-1, n = 5, K 
= 5x10-9 mol 
[94] 
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Name Reaction Function  Parameters Ref 
Fpn_ DAN export 2 * LIP_DAN ↔ Tf-Fe_ISF;  Fpn_DAN Biochemical hill 
function → 
a = 2 mol*(l*s)-1, n = 
1, K = 3x10-6 mol 
[127] 
Temporary Fe_ DAN 
use 
LIP_DAN → Mass action 
(irreversible)  
k = 5 x10-5 s-1  
Ferritin_ DAN 
expression 
→ Ferritin_DAN;  IRP_DAN Hill function -| a = 2.312x10-13 
mol*(l*s)-1, n = 1, K 
= 1x10-6 mol 
[122] 
Ferritin_ DAN 
degradation 
Ferritin_DAN → Mass action 
(irreversible) 
k = 1.203 x 10-5 s-1 [125] 
Ferritin_ DAN full 
degradation iron release 
Fe_within_ferritin_DAN → LIP_DAN;  Fe_within_ferritin_DAN 
Ferritin_DAN 
Mass action 
ferritin 
k = 1.203 x 10-5 s-1 [125] 
Ferritin_ DAN 
internalised iron release 
Fe_within_ferritin_DAN → LIP_DAN;  Fe_within_ferritin_DAN 
Ferritin_DAN 
Kloss Hill kloss = 13.1251 s-1 [125] 
Ferritin_ DAN iron 
binding 
LIP_DAN + Ferritin_DAN → Fe-ferritin_DAN Mass action 
(irreversible) 
k = 4.71 x 1010 
l*(mol*s)-1 
[125] 
Ferritin_ DAN iron 
internatlisation 
Fe-ferritin_DAN → Fe_within_ferritin_DAN + Ferritin_DAN Mass action 
(irreversible) 
k = 108000 s-1 [125] 
Ferritin_ DAN iron 
release 
Fe-ferritin_DAN → LIP_DAN + Ferritin_DAN Mass action 
(irreversible) 
k = 22922 s-1 [125] 
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Name Reaction Function  Parameters Ref 
Fe2 oxidation by H202 LIP_SN + H202 -> Fe3 + hydroxylRadical Mass action 
(irreversible) 
k = 2670 l*(mol*s)-1  
hydroxyl Radical to 
water 
hydroxylRadical -> Mass action 
(irreversible) 
k = 6.9 x 108 s-1 [149] 
Fe3 reduction by AS 
and O2 
Fe3 + O2 + AS -> LIP_SN Mass action 
(irreversible) 
k1 = 1 x 108 
l2*(mol2*s)-1 
[120] 
Iron binding to 
high_affinity_neuromela
nin  
NM_SN + Fe3 = NM-Fe_SN_high_affinity Mass action 
(reversible) 
k1 = 3.88 x 1011 
l*(mol*s)-1, k2 = 
2785.18 s-1 
[138] 
Iron released from 
high_affinity_neuromela
nin 
Fe_in_NM_SN_high_affinity -> Fe3;  Fe_in_NM_SN_high_affinity 
NM_SN 
Mass action 
(irreversible) 
k = 12 s-1 [138] 
High_affinity_neuromel
anin core formation 
NM-Fe_SN_high_affinity -> Fe_in_NM_SN_high_affinity Mass action 
(irreversible) 
k = 10098 s-1 [138] 
Iron binding to 
low_affinity_neuromela
nin 
NM_SN + Fe3 = NM-Fe_SN_low_affinity Mass action 
(reversible) 
k1 = 1.07 x 1011 
l*(mol*s)-1, k2 = 
10098 s-1 
[138] 
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! Results 
5.2.1! Iron concentrations in the DA neurone 
The result of a time course simulation performed at normal serum iron concentration, 
20 µM, over a time period of 80 years is shown in figure 5.4. The simulated 
concentration of LIP in the DA neurone is ~0.013 µM, which is around 10x lower 
compared to the concentration of LIP in the BBB and the BCB (shown in chapter 4, 
 
Figure 5.4 Time course simulations of the concentration of the metabolites in the DA neurone 
model responding to various levels of increased iron load. (A) The concentration of LIP in the DA 
neurone. (B) The concentration of iron in the ferritin in the DA neurone. (C) The concentration of 
iron at the high affinity binding sites of the neuromelanin in the DA neurone. (D) The concentration 
of iron at the low affinity binding sites of the neuromelanin in the DA neurone. The simulation was 
performed under normal conditions, Tf-Fe serum 20 µM, and is represented in bright blue. The 
curves representing Tf-Fe serum over than 30 µM overlaps.  
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figure 4.5). The time it takes to reach the steady state concentration is also much 
slower, 10 days vs 90 years. The concentration of the iron bound to the high affinity 
binding sites is ~145 µM at 80 years and keeps increasing linearly. The concentration 
of iron at the low affinity binding sites also increases linearly over the time course, 
however the concentration is ~0.06 µM around 2000 times lower than that at the high 
affinity binding sites. The total iron concentration in the neuromelanin at 80 years is 
estimated to be around 4530 ng iron/ mg neuromelanin, less than half of that compared 
to the concentration of iron in the SNpc neuromelanin experimental results of Zecca 
et al. (2006), shown in figure 5.5. In their paper, it was mentioned that the 
neuromelanin in the SNpc absorbed more iron during the isolation process, so the 
simulated concentration, which is between the concentration in the Locus Coeruleus 
and the SNpc, is within the range of possible in vivo concentration of iron in the 
neuromelanin. The concentration of iron in the ferritin is ~0.20 µM. This concentration 
is much lower than the iron concentration in the ferritin in the BBB and the BCB and 
the neuromelanin. The simulated concentration of ferritin protein in the DA neurone, 
5.53 nM, is also lower than in the BBB and the BCB (9.26 nM).  
 
Figure 5.5 (A) Simulated time course of the accumulation of the total iron concentration in the DA 
neurone (red curve) and the total iron in the neurone without the iron in neuromelanin. Most of the 
iron in the DA neurone is sequestered to the neuromelanin. (B) The Simulated iron concentration 
in neuromelanin, (Fe/NM = 4500  ng/mg neuromelanin), compared to the concentration determined 
experimentally in post– mortem LC (Locus Coeruleus) and SN (Substantia Nigra) tissue extracted 
from Zecca et al. (2006) [1]. 
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Time course simulations for varying levels of Tf-Fe in the serum were performed using 
the model to predict the delivery of iron into the neurone under higher concentrations 
of iron, shown in figure 5.5. As shown in figure 5.5 in chapter 4, the concentration of 
iron in the ISF when serum iron is higher than 30 µM, staying at a steady state of 23.5 
µM. Under this condition, the concentration of the metabolites in the DA neurone does 
not differ greatly from the concentration under normal iron conditions. The highest 
concentration of LIP in the DA neurone is 0.015 µM, which is still 10x lower than the 
normal concentration in the BBB or BCB. This value is also much lower than the 
concentration of labile iron that has been found to kill cells (1.2 µM) [135]. The 
concentrations of iron at the low affinity binding sites in neuromelanin are ~164 µM 
and ~0.07 µM, respectively. The concentration at the low affinity binding sites is much 
lower than the concentration at the high affinity binding sites. As the iron at low 
affinity sites has been linked to redox active complex [38], the model predicts that in 
normal condition, the concentration of this complex is low. 
5.2.2! Iron concentration in DA neurone in the PD/NBIA simulation 
The parameters for the expression rates for the proteins in the DA neurone were 
adjusted to the amount of protein found in the literature for NBIA and PD conditions, 
as described in materials and method section (section 5.1). The time course simulation 
was then performed under the same serum iron conditions for the control condition, 
shown in figure 5. 6. The concentration of the iron in the DA neurone is generally 
higher in the PD/NBIA simulation compared to the control. The concentration of LIP 
in the DA neurone at steady state is ~0.38 µM under normal serum iron conditions. 
This value is almost 30x higher than for the control condition and twice those in the 
LIP in the BBB and the BCB.  
The concentration of iron in ferritin in the DA neurone reaches a steady state of ~2.8 
µM at around ~80 years. This value is around 10x higher than for the control condition. 
The concentration of ferritin protein is 2.61 nM, half the concentration in the control 
condition. The concentration of the iron in the high affinity binding sites is ~4300 µM 
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at 80 years and keeps increasing in a linear fashion. The concentration of iron at the 
low affinity binding sites also increases linearly over the time course, reaching a 
concentration of ~1.8 µM at 80 years.  
Time course simulations for varying levels of Tf-Fe in the serum were performed using 
the PD/NBIA model to predict the delivery of iron into the neurone under higher 
concentrations of iron, and are shown in figure 5.6. For a high serum iron 
concentration, the concentration of LIP in the DA neurone saturates at 0.43 µM, which 
is higher than the normal concentration in the BBB or BCB. However, this value is 
still lower than the value at which redox damage in cells was observed (1.2 µM)[135]. 
 
Figure 5.6 Time course simulations of the concentration of the metabolites in the DA neurone model 
responding to various levels of increased iron load in the  PD/NBIA simulation. (A) The 
concentration of LIP in the DA neurone. (B) The concentration of iron in ferritin in the DA neurone. 
(C) The concentration of iron at the high affinity binding sites of neuromelanin in the DA neurone. 
(D) The concentration of iron at the low affinity binding sites of neuromelanin in the DA neurone. 
The simulations performed under normal conditions, where Tf-Fe serum of 20 µM, is represented 
in bright blue. 
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The concentration of iron at the high and low affinity binding sites in neuromelanin 
reached ~4800 µM and ~2.0 µM, respectively, at 80 years. The concentration of iron 
in the ferritin saturates at 3.3 µM with increasing serum iron. The time course 
simulations for varying serum iron concentrations predict that even under PD/NBIA 
condition the concentrations of the metabolites in the DA neurone do not differ greatly 
from the concentration for normal iron concentrations. The differences between the 
metabolite concentrations in the control condition and PD/NBIA simulation are much 
more significant than differences caused in the variation in the serum iron 
concentration, especially for iron in neuromelanin. 
5.2.3! Metabolic control analysis 
MCA was performed to investigate the reactions that have the greatest effect on the 
concentration of iron in the DA neurone. The Reder algorithm alone was used for this 
model, as the results in the previous chapter have shown that it is more suitable for 
this model. The result of the MCA calculations produced a concentration control 
coefficient for the metabolite of interest describing how much the rates of the various 
reactions in the model affect the metabolite’s concentrations. The MCA results for the 
LIP in the DA neurone, iron at the high affinity binding sites of neuromelanin, and 
iron bound to the high and low affinity binding sites of neuromelanin are given in 
tables 5-2, 5-3, and 5-4, respectively.  
The MCA results for the LIP show that the reactions that have the most control are the 
expression and degradation of TfR, the binding of Tf-Fe to the TfR in the BBB, BCB 
and the DA neurone. The export of iron out of the neurone by ferroportin also has 
similar effect as the TfR reactions on the LIP. The expression and degradation of 
ferroportin also have an impact on the LIP, but half the extent of the TfR and 
ferroportin. The expression and degradation of IRP in the BBB, the BCB and the DA 
neurone also have an influence on the LIP concentration. LIP is more prone to be 
involved in the radical generation than other types of iron in the neurone that are bound 
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to proteins, so the dysregulation in one of these reactions has a higher probability to 
cause cell damage by redox radicals. 
Table 5-2 MCA concentration control coefficient (CCC) for LIP in the DA neurone 
LIP in DA neurone 
reaction CCC 
(TfR1_BBB expression) 0.957 
(TfR1_BBB binding 1) 0.957 
(TfR1_BBB degradation) -0.957 
(TfR1_BCB_apical degradation) 0.957 
(TfR1_BCB_apical expression) -0.957 
(TfR1_BCB binding 1) -0.957 
(TfR1_SN binding 1) 0.956 
(TfR1_SN expression) 0.956 
(Fpn_SN export) -0.956 
(TfR1_SN degradation) -0.956 
(IRP_BBB expression) 0.447 
(IRP_BBB degradation) -0.447 
(IRP_BCB degradation) 0.447 
(IRP_BCB expression) -0.447 
(IRP_SN expression) 0.395 
(IRP_SN degradation) -0.395 
(Fpn_SN degradation) 0.320 
(Fpn_SN expression) -0.320 
(Fpn_BBB export) 0.255 
(Fpn_BCB export) -0.255 
 
The concentration control coefficient with the Reder MCA for the concentration of 
iron at the high and low affinity binding sites shows that oxidation and reduction of 
the LIP in the neurone have a great effect on the iron concentration at the neuromelanin   
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Table 5-3 MCA concentration control coefficient (CCC) for the concentration of iron at the high 
affinity binding sites of neuromelanin in the DA neurone. 
Fe in the neuromelanin: High affinity binding sites 
reaction CCC 
(Fe2 oxidation by H202) 1.001 
(Fe3 reduction by AS and O2) -1.001 
(iron released from high_affinity_neuromelanin) -1.000 
(TfR1_BBB binding 1) 0.958 
(TfR1_BBB expression) 0.958 
(TfR1_BBB degradation) -0.958 
(TfR1_BCB_apical degradation) 0.958 
(TfR1_BCB_apical expression) -0.958 
(TfR1_BCB binding 1) -0.958 
(TfR1_SN binding 1) 0.958 
(TfR1_SN expression) 0.958 
(Fpn_SN export) -0.958 
(TfR1_SN degradation) -0.958 
(iron binding to high_affinity_neuromelanin) 0.784 
(IRP_BBB expression) 0.448 
(IRP_BBB degradation) -0.448 
(IRP_BCB degradation) 0.448 
(IRP_BCB expression) -0.448 
(IRP_SN expression) 0.395 
(IRP_SN degradation) -0.395 
(Fpn_SN degradation) 0.320 
(Fpn_SN expression) -0.320 
(Fpn_BBB export) 0.255 
(Fpn_BCB export) -0.255 
(high_affinity_neuromelanin core formation) 0.216 
 
 
 
 
115 
Table 5-4 MCA concentration control coefficient (CCC) for the concentration of iron at the low 
affinity binding sites of neuromelanin in the DA neurone. 
Fe bound to the neuromelanin: Low affinity binding sites 
reaction CCC 
(Fe2 oxidation by H202) 1.001 
(Fe3 reduction by AS and O2) -1.001 
(TfR1_BBB binding 1) 0.958 
(TfR1_BBB expression) 0.958 
(TfR1_BCB_apical degradation) 0.958 
(TfR1_BCB_apical expression) -0.958 
(TfR1_BCB binding 1) -0.958 
(TfR1_SN binding 1) 0.958 
(TfR1_SN expression) 0.958 
(Fpn_SN export) -0.958 
(TfR1_SN degradation) -0.958 
(IRP_BBB expression) 0.448 
(IRP_BBB degradation) -0.448 
(IRP_BCB degradation) 0.448 
(IRP_BCB expression) -0.448 
(IRP_SN expression) 0.395 
(IRP_SN degradation) -0.395 
(Fpn_SN degradation) 0.320 
(Fpn_SN expression) -0.320 
(Fpn_BBB export) 0.255 
(Fpn_BCB export) -0.255 
  
 
 
 
116 
high binding sites. The expression and degradation of TfR, the binding of Tf-Fe to the 
TfR in the BBB, BCB and the DA neurone have a great impact on the concentration 
of iron in neuromelanin. The expression and degradation of IRP and ferroportin in the 
BBB, the BCB and the neurone also have an effect on the concentration of iron in the 
neurone, though to a lesser extent. 
! Discussion 
An increase in iron in the SNpc is a marker of PD, but the role of iron in the progression 
of the disease is not completely understood. The novel computational model 
introduced in this chapter was created to investigate the uptake of iron into the DA 
neurone in the SNpc. The parameters used in the model were derived from multiple 
published experimental studies. PD and a NBIA phenotype that shows similar iron 
deposition in SNpc as is observed in PD, were reproduced by simulating a modified 
expression of proteins involved in iron regulation in the neurone.  
Time course simulations of the model were performed under normal iron 
concentration conditions. The concentration of labile iron in the DA neurone is quite 
low, around 10x lower than the concentration of iron in the BBB and the BCB. Even 
after saturation, the steady state concentration of the labile iron is still low, less than 
the value found to induce cell death in the pituitary cells in published experiments 
[135]. In comparison, the concentration of iron in neuromelanin is almost 1000 times 
higher, illustrating that neuromelanin is the iron sequesterer in the neurone. This is 
also shown by the huge difference in concentration between the total iron 
concentration in the DA neurone and the total iron concentration with iron in the 
neuromelanin excluded in figure 5.5 (A). The concentration of iron in ferritin in the 
neurone is very low compared to neuromelanin. The model thus predicts that ferritin 
does not play a huge role in iron regulation in this neurone. 
The simulated concentration of iron in neuromelanin was compared to the 
experimental concentration measured by Zecca et al. (2006) [1] in figure 5.5. The 
 
 
 
117 
simulated concentration at 80 years lies between the concentration of iron in the 
neuromelanin in the Locus Coeruleus and the SNpc. Although the simulated value is 
not close to the experimental value, it was discussed in the paper that neuromelanin 
may sequestered additional iron during isolation from the SNpc tissue due to the high 
iron concentration in the region.  
The results from the MCA simulations show that the protein that has the most control 
over the concentration of LIP in the DA neurone and iron in neuromelanin is TfR, 
followed by FPN and IRP. FPN and IRP were two of the proteins which expression 
were changed for the PD/NBIA simulation. The model simulated PD/NBIA condition, 
based on an estimated increase in proteins found in the published literature [151]. The 
total iron concentration in the DA neurone in PD/NBIA simulation is higher than for 
the control, as has been shown in the published literature [17]. The concentration of 
labile iron in the neurone remains relatively low. Most of the iron is sequestered in the 
neuromelanin, as in the control case. However, the simulated concentration of iron in 
neuromelanin under PD/NBIA condition is 10 times the concentration of iron in the 
neuromelanin in a healthy SNpc, from Zecca et al. (2001) [146]. At this concentration, 
neuromelanin may have become pro-oxidant and cause cell damage.  
Time course simulations with different serum iron were performed under normal and 
PD/NBIA condition, as shown in figure 5.4 and 5.6. The graphs illustrate that the 
different concentrations of serum iron in both conditions do not have a strong effect 
on the concentration of labile iron in the DA neurone or iron in the neuromelanin. 
While the dysregulation in the protein expression has a much greater impact on iron 
uptake and iron concentration in the DA neurone, as can be concluded by comparing 
the concentration of iron in the DA neurone in health and PD/NBIA simulation, under 
the same serum iron concentration. If cell death in DA neurones in PD is caused by 
the generation of free radicals by iron, then dysregulation of the proteins, such as 
shown in the PD/NBIA simulation, could be the likely cause. 
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The thesis work is about developing new models that could be used to explore the iron 
regulation in the brain and how it changes, and might be treated, in Parkinson’s disease 
(PD). The synchrotron work, particularly the scanning transmission X-ray microscopy 
(STXM) measurement of organic and inorganic materials, offer new dataset to inform 
the model. The results from the synchrotron work and computational modelling show 
how each method has its own advantages for looking at this problem from a different 
direction and how they complement each other.  
! Cell to neuropil iron concentration ratio determined by 
SXRF 
In this study, synchrotron X-ray fluorescence (SXRF) maps of the SNpc region taken 
prior to this project for control and PD cases were processed and analysed. The aim 
was to produce a ratio of the concentration of iron in the individual dopaminergic (DA) 
neurones and the surrounding neuropil in both cases. This quantification is of interest 
because the DA neurone is one of the cells affected in PD and also the compartment 
modelled in chapter 5. The ratio could be used to validate the model or to adjust the 
model parameters to reproduce the concentration ratio. However, the small sample 
size was not conducive for producing a statistically robust ratio of the iron 
Chapter 6! Conclusions and future work 
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concentration in the cells and neuropil, and the work included here simply serves as 
an illustration of how this method might be used in more quantitative work in future. 
SXRF allows high spatial resolution mapping of the region of interest, better than 100 
nm at some beamlines [88]. In the future, with a complementary optical image of the 
map area, the dopaminergic neurones can be differentiated and segmented from the 
neuropil. Then, the intensity of the iron signal in and out of the cell can be calculated 
and compared. Absolute concentration, not relative concentration, can also be 
calculated by using the photon flux from a reference material of known iron 
concentration. This flux can be used to convert the peak areas to concentration. The 
calculated concentrations from the SXRF measurement could be used to validate the 
computational model or for parameter estimation to improve the model. Therefore, the 
results from future work using SXRF would present an effective quantitative 
technique for post-mortem tissue to calculate the concentration of iron in the cells and 
the surrounding area. 
! Neuromelanin in the DA neurone 
In the collaborative STXM analysis described in chapter 3, it is the first time STXM 
energy spectra have been obtained from neuromelanin. The result shows a feature in 
the energy spectrum at 286 eV that may be specific to neuromelanin. It is also the first 
time this energy has been linked to neuromelanin. This energy was chosen because the 
map at this energy shows only the distinct granular structures and not the surrounding 
tissue (off-peak energy for the tissue). The comparison of this granular structure to the 
visible neuromelanin granule in the optical image of the resin-embedded tissue section 
revealed that they are analogous to each other. This finding is still at an early stage, 
more imaging and comparison have to be made to determine if this energy peak is 
specific to neuromelanin structure. The next step would be to compare the structure 
map using STXM to the adjacent stained section, to determine if the structure seen at 
286 eV match the neuromelanin structure. 
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When an X-ray absorption energy has been determined to be specific to neuromelanin 
structure, then together with the iron map, a composite map showing the iron inside 
the neuromelanin can be produced. This method will allow an accurate diagnosis of 
the presence of iron and its redox state in the neuromelanin in the tissue at high spatial 
resolution. The result from this observation can be applied to the computational 
modelling of neuromelanin in the DA neurone. The neuromelanin in the current model 
stores Fe3+ and this complex is assumed not redox active. However, should Fe2+ be 
found in the neuromelanin in control or PD, the way the neuromelanin is modelled 
should also change. Following further investigation, a reaction for the reduction of 
iron in the neuromelanin, for example, may be added. 
! Ferrous and zero valent iron in the SNpc in PD 
One of the aims of this project was to study the compartmentalisation of iron 
deposition in the SNpc tissue. In chapter 3, STXM was applied to investigate this in 
both a control and PD case. This study was pilot work for a new analytical approach 
implementing STXM to study human tissue, and in this project, to do so in the context 
of PD. STXM allows images of a biological sample in its natural (unstained) state to 
be taken, and because it can be conducted non-destructively, it permits measurements 
of multiple organic and inorganic compounds in a single tissue section.  
The STXM result shows that iron found in the control tissue is exclusively in Fe3+ form 
and the iron found in the PD tissue includes Fe2+ and zero valent iron (Fe0). Non-heme 
iron in human is mostly ferric, and bound to transferrin or stored in ferritin. Iron in 
these forms is not likely to be involved in a redox reaction that produces reactive 
oxygen species (ROS), so the finding of Fe3+ in control tissue is expected. Fe2+ is low 
in abundance and highly reactive, it is associated with the labile iron pool, and its 
presence in tissue has been implicated in the occurrence of redox reactions that 
generate ROS and cause subsequent cell damage and death. Thus, the observation of 
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Fe2+ in PD tissue supports the hypothesis that iron-induced redox stress is a 
contributing factor to cell death in SNpc in PD. 
 
 
Figure 6.1 (A) Tissue structures of human putamen (left) and amygdala (right) taken at oxygen 
K-edge energy 532.1 eV. (B) Speciation maps of a protein deposit in human amygdala tissue with 
Alzheimer’s disease. Acquisition energies: carbon K-edge (285.2 eV; protein), calcium L-edge 
(352.6 eV), oxygen K-edge (533.8 eV; carbonate (CO)), potassium L-edge (300 eV) and iron L-
edge (710 eV). Composite image created using colours indicated in the individual map panels. 
Scale bars 2 µm. (C) Iron L-edge X-ray absorption spectra of the two iron deposits identified in 
the iron panel map in (B). [151] 
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The study here involved only one control and one PD case. This study was designed 
to determine the feasibility of analysing these fragile, chemically unfixed post-mortem 
human brain tissue samples using STXM. The result shows that both control and PD 
samples are feasible; both can withstand the tissue processing and STXM analysis, so 
that in the future, with more samples, statistical comparisons between groups can be 
obtained. We have already started to showcase the method in our demonstration of 
human brain amygdala tissue analysis by STXM, which is to our knowledge the first 
application of STXM to intact human brain tissue, as shown in figure 6.1 [153]. Zero 
valent iron spectra were also detected from the PD tissue, and to the best of our 
knowledge this is the first observation in PD tissue. Recently, we reported evidence of 
zero valent iron in human amyloid plaque cores using STXM [105]. This shows the 
high sensitivity of the technique and that with the original protocol development work 
done for this thesis, and the subsequent application, STXM is emerging as a powerful 
technique to study the organic and inorganic content of human brain samples. 
! Synchrotron imaging: challenges faced and future 
opportunities 
For the samples as shown in figure 3.9 for the STXM, the tissue architecture is very 
fragile following traditional frozen archiving of the bulk samples at brain banks, and 
some of the iron detected is not directly associated with well-defined tissue structures. 
This complication should not affect the observation of the redox state of iron found in 
the region, but the location of this iron cannot reliably be related to structures within 
the tissue when the tissue architecture is damaged. In addition to freeze-thaw damage, 
the possible reasons the tissue is in this condition are due to the nature of the tissue 
itself caused by the disease or damage arising during sample embedding.  
The condition of the PD case tissue sample, figure 3.11, prepared during the same time 
is not as damaged as the control tissue presented in figure 3.9. As cell death is not 
expected to the same extent in the control tissue, the damage is most likely caused by 
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the tissue preservation so a better tissue preservation method is recommended in the 
future. An example is the plunge freezing method to preserve the tissue. Plunge 
freezing method relies on the theory that crystallisation of ice does not occur under the 
cooling rates of 103 – 104 °C/s [154], this would mean minimal damage to the tissue 
caused by freezing.  
Optimising the detection limits of the experiment is the most important factor in being 
able to analyse the iron. However, another challenge is that labile or weakly-bound 
iron might not be retained in the tissue. The possible cause for any loss of the iron is 
that some fraction of the iron has been washed away during the sample preparation 
process. To preserve all forms of iron during the sample preparation/ embedding in 
the future, the proposed plan is to use cryo ultra-microtome sectioning [155]. By using 
this sectioning method, the samples do not have to be dehydrated and embedded in the 
resin. The tissue can be sectioned in a frozen state. This sectioning has been used to 
prepare samples for transmission electron microscopy. The samples to be sectioned 
have to be fixed with a sucrose solution to avoid the samples from breaking during 
sectioning. However, the sucrose solution may change the chemical state of the iron 
in the sample, so this method is not currently viable to be applied to the sample 
preparation in this thesis. Another Ph.D. student in the group is currently developing 
a cryo-ultramicrotomy method that will not require the usage of fixative so that it will 
be compatible with the purpose of the STXM measurement. 
! Evaluating the computational model of brain iron 
metabolism in health 
The blood brain barrier (BBB) model is presented in this thesis because BBB is the 
iron point of entry into the brain and it has been shown in the literature that it regulates 
the iron homeostasis in the brain [39]. To investigate the dysregulation of iron in PD, 
it is essential to understand how iron is taken into the brain. This thesis presents the 
most comprehensive computational model of the iron transport in the brain barrier 
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systems (the BBB and the brain cerebrospinal fluid barrier (BCB)) metabolism to date. 
The only existing model on the iron transport into the brain was developed by Simpson 
et al. (2014) [134], and their model mainly focused on the transport of iron from blood 
into the brain. Although it was mentioned in the experimental part of their paper that 
the regulation of transferrin receptor in the BBB takes place, the model does not 
include the regulations of TfR and other proteins expressions by iron regulatory 
protein (IRP) [134]. The barrier model in this thesis includes the regulatory reactions 
by IRP and an improved iron binding and internalisation into the ferritin. It also has 
more realistic compartments and transport flux (blood – BBB – interstitial fluid (ISF) 
– cerebrospinal fluid - BCB – blood). 
In the construction of the brain barrier systems model, parameter estimation was not 
performed to obtain the parameters of individual reactions. Parameter estimation is 
usually used to derive the most highly optimised kinetic parameters to fit the 
experimental data. The consequence of not executing parameter estimation is that the 
confidence of the parameter fit may be unknown because the authors would have 
performed their curve fitting and may not have mentioned the confidence level. Even 
without performing parameter estimation, the current brain barrier systems model 
performs well as the barriers protect the brain compartment against iron overload, as 
reflected in experimental data. Doing parameter estimation in the future, when 
experimental data for the kinetics of the metabolites in the BBB and BCB are 
published, may enable refinement of the model. Performing parameter estimation for 
all kinetic parameters may be redundant because the model may not be sensitive to 
some of the parameters, and it may only be necessary to do this for TfR expression 
and degradation, as discussed below. 
The model presented here has not been through extensive quantitative validation due 
to the limited availability of published data, but it has replicated the binding curve of 
transferrin bound iron (Tf-Fe) to TfR and captures the dynamics of the concentration 
of iron in the ISF in response to iron injection described in the literature [130, 131]. 
The metabolic control analysis (MCA) of the model indicates that the TfR controls the 
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uptake of the iron into the ISF, in agreement with the convention that TfR regulates 
the iron uptake in the BBB. When experimental data for TfR expression and 
degradation in BBB and BCB by IRP become available, performing parameter 
estimation on these may improve the performance of the model. 
An iron overload simulation shows that the in silico BBB model is able to regulate the 
iron concentration in the ISF to a safe level. The simulation result reveals that in health 
the BBB and the BCB are able to maintain their labile iron pool (LIP) concentration 
at a level that does not cause redox-induced cell death in different conditions of 
systemic iron overload. The model postulates that the BBB and BCB are capable of 
maintaining intracellular iron homeostasis, even under conditions of systemic iron 
overload, and thereby protecting the brain and the barriers from iron mediated 
oxidative stress. This supports the concept of the function of the BBB and the BCB as 
the brain’s protective barrier systems, specifically in terms of preventing brain iron 
overload in healthy human [21].  
A simulation of iron deficiency in brain ISF, arising from an increase in iron uptake 
by nearby neuronal cells, is shown in figure 4.9. The purpose of the simulation was to 
investigate how the brain barrier systems model would behave when the concentration 
of iron in the ISF was reduced because of an increase in iron uptake by nearby neuronal 
cells. The simulation results show that the brain barrier systems model does not 
increase the iron uptake into the ISF to regulate this potential iron deficiency 
condition. The simulated concentration of iron in the BBB stays at the steady-state 
level. The barrier systems model does not transport more iron out of the barriers into 
the ISF to compensate for the reduced concentration of iron in the ISF. 
The human brain barrier systems are postulated to perform a major role in regulating 
brain iron levels, so feasible explanations for why the barrier systems model does not 
compensate for lowered iron in the ISF, by exporting more iron from inside the barriers 
into the ISF, are as follows:  
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(1) To prevent even more iron being taken up into neuronal cells. In this scenario, the 
brain barrier systems are doing their proposed job as the brain iron regulatory system.  
(2) Because a regulatory protein or mechanism that is responsible for detecting and 
regulating the iron deficiency condition was not accounted for in this model; this may 
be a protein or mechanism that is as yet unknown. Hepcidin is the only known enzyme 
to have this regulatory role in systemic iron uptake because it is the enzyme that 
controls the degradation of the only known iron exporter, ferroportin. However, the 
presence of hepcidin in, or in the vicinity of the BBB, is still debated because the 
evidence for hepcidin mRNA in the brain is scarce [136].  
The model allows for a more extensive investigation of the iron uptake into the brain 
across the BBB and BCB under different conditions of systemic iron availability. This 
makes it possible to evaluate the effects of varying concentrations for proteins that are 
responsible for iron regulation, the effect this has on the concentration of iron 
transported into the ISF and, thereby, the effect on iron concentration reaching the 
tissues of the brain. The model has also predicted the presence of a new metabolite 
that has a vital role in sensing the brain iron concentration and regulating iron transport 
into the brain, a prediction which could be studied in future experimentally. 
! Evaluating the computational model of SNpc DA 
neurone iron metabolism in health and neurodegenerative 
condition 
To investigate the role of iron in PD, the barrier model was expanded to include a 
compartment that represents the DA neurone in the SNpc. The DA neurone simulation 
in this thesis is the first quantitative model of iron trafficking into the neurone. The 
model allows the user to explore how iron in the brain is transported into, and stored 
in, the DA neurone. 
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One of the main features of the DA neurone is the dark pigment called neuromelanin. 
Among its many roles, Neuromelanin is understood to be protective by sequestering 
potentially toxic metals, such as iron [156]. The DA neurone model simulation, figure 
5.4, shows that most of the iron concentration in the neurone is bound to the 
neuromelanin, resulting in a low LIP in the neurone. This simulation result is in 
conceptual agreement with the experimental observations that led to the hypothesis 
that neuromelanin has a protective role [157] .  
The simulated iron concentration in the neuromelanin in the DA neurone, 4500 ng/mg 
NM, lies between the concentration of iron in the isolated Locus coeruleus (~2000 
ng/mg NM) and isolated SNpc (~11000 ng/mg NM) measured by Zucca et al. (2006) 
[1]. While the simulated concentration does not match the experimental concentration, 
it was mentioned in the paper by Zucca et al. (2006) [1], that the higher concentration 
measured in the SNpc was caused by the neuromelanin absorbing more iron during 
the isolation process. Since the iron concentration in the Locus coeruleus is lower than 
the SNpc, the simulated concentration lies in the possible range of neuromelanin iron 
concentration in vivo.  
Iron bound to the low affinity binding sites of the neuromelanin has been proposed to 
remain redox active [59]. In the simulated healthy condition, increasing the 
concentration of serum iron doubled the concentration of iron in the low affinity 
binding sites of the neuromelanin. By comparison, in the PD / neurodegeneration with 
brain iron accumulation (NBIA)  simulation, the concentration of the iron in the low 
affinity sites of the neuromelanin is approximately 33% higher than the concentration 
of iron in the simulated healthy condition. Therefore, the increase of potentially redox 
active iron in the neuromelanin (the iron associated with the low affinity binding sites) 
is substantially higher in the NBIA condition, where the expression of several proteins 
responsible for iron homeostasis were dysregulated to be consistent with results 
obtained in independent experiments with an  A2β (iPLA2β)-KO animal model of a 
general form of NBIA [151]. The results from this simulation are consistent with 
protein dysregulation playing a more significant role than an increase in serum blood 
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iron concentration in ROS-induced cell death in brain iron accumulation disorders 
[158]. 
According to the MCA, the TfR expression and degradation in the BBB, BCB and DA 
neurone is one of the key regulators for the concentration of LIP in the DA neurone 
and for iron in the neuromelanin. When experimental data for TfR expression and 
degradation in BBB and BCB by IRP become available in the future, performing 
parameter estimation on these may improve the performance of the DA neurone 
model. From the MCA result, it can be deduced that the integrity of the BBB and the 
BCB, especially the TfR level, may directly affect the exposure of the DA neurone to 
iron-induced redox stress. 
One of the aims of this project was to build a computational model of the iron transport 
into the DA neurone of the SNpc that allows for investigation of iron dysregulation in 
health and PD, and to create simulations to test theories about why DA neurone cells 
in the SNpc are affected in the PD. This aim was nearly fulfilled because in this study 
the model was used to computationally recreate the condition found in both PD and 
NBIA. The NBIA experimental data incorporated to inform the development of the 
model were taken from an animal model with prominent iron deposition in the SNpc, 
and a similar iron accumulation pathway as evidenced in PD. The results from the 
simulation of the iron accumulation condition led to the hypothesis presented in this 
thesis that DA neurons in PD are vulnerable to ROS induced cell death as a result of 
the dysregulation of metabolite expression and degradation. 
! Computational model limitations and future 
opportunities 
There are limited quantitative human data available for model parameterisation. The 
model used data from multiple other sources such as the animal experiment data and 
in vitro data. In cases where no human brain data were available, the model 
incorporated data from other human cell types. The quality of these data place limits 
on the efficacy of the model.  
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Another limiting factor is the scope of the model presented here. The model only 
includes a part of the iron transport mechanism in the body. It does not include: 
•! Other cell types that surround the DA neurone – these cells, such as glia cells 
that are rich in iron, may have an impact on the iron transport into the DA 
neurone. The model compartment of such cells would be connected directly to 
the ISF compartment, so they could acquire iron via the BBB independently of 
the neurones, and should not have great effect on the iron uptake into the DA 
neurone.  
•! Specific cell populations from other regions of the brain - the accumulation of 
iron in certain areas of the brain is associated with neurodegenerative diseases, 
such as iron accumulation in the substantia nigra in PD and in the putamen in 
Alzheimer’s disease (AD) [159]. The reason why iron accumulates only in 
these regions is still under investigation. The current model is not capable of 
investigating this problem. An extended version of the model that contains 
specific mechanisms of iron loading in other regions of the brain may reveal 
how the heterogeneous distribution of iron in the brain arises in health and 
disease, including factors causing regional accumulation. 
•! Other proteins or reactions that may be important in the uptake of iron in these 
compartments – alpha-synuclein is not included in the model. The aggregation 
of alpha-synuclein in the presence of iron has been shown repeatedly, however, 
the role of iron in this aggregation is not fully understood [160]. Once the 
interaction is better understood, the addition of alpha-synuclein to the model 
should allow the impact of alpha synuclein on iron regulation in PD to be 
modelled.  
•! The complexity of some of the reactions – the ferritin has two subunits and the 
ratio of these subunits is affected by the cell types and iron status. In the model, 
the ferritin is modelled as a single protein, therefore, the model could not 
predict the ferritin subunit ratios and the cell-specific ferritin type could not be 
simulated using the model. Neuromelanin was modelled in this study in a 
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similar way to how ferritin was modelled because the iron binding structure in 
neuromelanin is similar to ferritin [58]. This might place a limit on how well 
the model replicates the dynamic of iron binding to neuromelanin. A better 
understanding of the binding mechanism of iron to neuromelanin may improve 
the current model. 
•! Metabolism of other metals that may affect the iron uptake process - Copper 
uptake in to the brain shares similar transporter as the iron uptake, such as 
DMT1 and the caeruloplasmin, and its dysregulation in the brain has been 
implicated in neurodegenerative diseases. In the BBB and the BCB, DMT1 has 
been shown to also mediate the transport of copper and may inhibit the 
transport of iron by DMT1 [7]. The ferrireductase caeruloplasmin that oxidises 
newly released Fe2+ from the BBB to Fe3+, is also a copper carrier. Care should 
be taken when interpreting the results of iron metabolism that may be impacted 
by other metabolic process. An extended model that includes the copper 
metabolism would be able to investigate the role of copper in the diseases that 
also exhibit altered iron handling, such as Wilson’s disease and 
aceruloplasminemia [161]. The concentration of copper has been found to 
decrease in the SNpc in PD [162]. The extended version of the model that 
includes the copper uptake into the DA neurone may be useful in the 
investigation of this finding. 
Metabolic control analysis (MCA) is applied in the computational analysis to 
determine the key reactions that affect the concentration of iron in the different 
compartments in the model. In COPASI, there are two algorithms available, the Reder 
algorithm and the Smallbone algorithm. According to the literature [163], the 
Smallbone algorithm has overcome the Reder algorithm’s limitation, which is that the 
algorithm is only valid if the matrix in the equation is of full rank. The Smallbone 
method directly chooses the linearly independent rows of the matrix so that the matrix 
is of full rank. However, the calculation of the metabolic control analysis using the 
Smallbone algorithm shows the control coefficient of the expression of the IRP in the 
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BBB and the BCB to be zero for all metabolites, which does not fit the role of IRP as 
the protein that regulates many of the transport proteins in the model. Therefore, in 
this thesis, the Reder algorithm were used to interpret the key factors of the brain iron 
metabolism. The results from the Reder algorithm calculation was compared to the 
result of generic sensitivity analysis and they reveal results leading to a similar 
conclusion. 
6.7.1! Future modelling experiment opportunities 
The models presented have a great potential for expansion in size and detail. This 
section presents opportunities to develop the model in the future, developments that 
were not undertaken here due to time constraints. 
The clinical study using iron chelator for PD patient, done by Devos et al. (2014) [20] 
shows great potential to be an effective therapy to remove iron from the SNpc in PD. 
Deferiprone (DFP), the drug used in the study, was shown to be able to cross the BBB 
and affect the SNpc [164]. An extended version of the model that includes a metabolite 
that mimics the function of DFP would be a powerful tool to investigate the possible 
mechanism of action of DFP that is not yet demonstrated in the literature, as well as 
its effect on the iron uptake mechanisms in the BBB and DA neurone. The extended 
version may also be useful in improving treatment design with DFP, or in the 
development of an improved iron chelating drug for PD. 
The modelling of the hypoxia – inducible factor-2a (HIF – 2) into the existing 
compartments in the model would create a more extensive model that would include 
the iron uptake into the brain in response to hypoxia. The HIF – 2 responds to the 
hypoxic condition and the iron level in the cells by modulating the expressions of 
proteins such as TfR and DMT1 in the body [165, 166]. Dr Tracey Rouault2 has 
suggested that although the roles of HIF-2 in the BBB has not been experimentally 
studied, it is logical to assume it plays similar role in the barrier because it is highly 
                                                
2 Private communication received on March 2018 
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expressed in the brain capillaries [167] and is responsive to the iron and oxygen level. 
The addition of reactive oxygen species (ROS) to this extended model will assist the 
study of the possible role of ROS in the regulation of HIF-2. Moreover, the ROS 
modelling will improve the understanding of the formation of toxic radicals that 
produce oxidative stress and the possible discovery of targets for reducing the damage 
caused by oxidative stress in PD and other neurodegenerative diseases.  
Another area where the modelling of ROS, HIF and iron transport will be useful is for 
brain tumours. The increase in ROS, HIF and TfR are implicated in the development 
or survival of neoplastic cells [168]. Recent studies have also suggested that these cells 
became more malignant, they increase the production of hepcidin to decrease the 
concentration of iron exporter, ferroportin, so that they can retain more iron [169]. A 
similar model to the current model, but tailored to the transport in the neoplastic cells, 
would provide a tool to investigate further the flux or concentrations of the metabolites 
of interest with lower cost and time consumed than an animal or in vitro model. 
Potential therapeutic solutions can be tested before application to animal models to 
increase the successful chance of the experiment and minimize the use of the 
laboratory animals. 
A further point made by Dr Tracey Rouault2 is the possibility that the basal ganglia 
function is analogous to that of the liver, storing iron and releasing hormones that 
control the transport of iron in the brain. Once the metabolites present in the basal 
ganglia are better identified, an initial model could be developed to assess the 
regulatory contribution from the basal ganglia. The current model shows a good 
regulatory mechanism in response to iron overload, but does not appear to respond to 
an iron drop in the ISF. The addition of the basal ganglia compartment may overcome 
this problem. 
In summary, this thesis presents the most complete model of the computational model 
of the iron transport in the brain barrier systems (the BBB and the BCB) metabolism 
to date and a novel model of the computational model of the iron transport in the DA 
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neurone. The method development work to perform the STXM analysis of SNpc tissue 
has shown strong potential for subcellular redox state analysis and label-free imaging 
of the organic material. This includes a spectral feature that may be specific to 
neuromelanin. In combination, the advances in computational modelling and 
analytical measurement create an opportunity to improve understanding of iron 
dysregulation in the human brain. 
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